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A B S T R A C T
Background
Acute otitis media (AOM), or acute middle ear infection, is one of the most frequently occurring childhood diseases, and the most
common reason given for prescribing antibiotics in this age group. Guidelines often recommend antibiotics as first-line treatment for
severe AOM. However, antibiotics also lead to antibiotic resistance, so preventing episodes of AOM is an urgent priority.
Objectives
To assess the effects of probiotics to prevent the occurrence and reduce the severity of acute otitis media in children.
Search methods
We searched CENTRAL, PubMed, Embase, and three other databases (October 2018), two trial registers (October 2018), and
conducted a backwards and forwards citation analysis (August 2018). We did not apply any language, publication date, or publication
status restrictions.
Selection criteria
Randomised controlled trials (RCTs) of children (aged up to 18 years), comparing probiotics with placebo, usual care, or no probiotic.
Data collection and analysis
Two review authors independently assessed the eligibility of trials for inclusion and risk of bias of the included trials, and extracted data
using pre-piloted data extraction forms. We analysed dichotomous data as either risk ratio (RR) or odds ratios (OR) and continuous
data as mean differences (MD).
Main results
We included 17 RCTs involving 3488 children, of which 16 RCTs were included in the meta-analyses. Of the 16 RCTs that reported
the mean age of children, mean age overall was 2.4 years; in 4 RCTs the mean age of children participating in the trial was less than 1
year old; in 2 RCTs the mean age was between 1 and 2 years old; and in 10 RCTs the mean age was older than 2 years. Probiotic strains
evaluated by the trials varied, with 11 of the included RCTs evaluating Lactobacillus-containing probiotics, and six RCTs evaluating
Streptococcus-containing probiotics.
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The proportion of children (i.e. the number of children in each group) experiencing one or more episodes of AOMduring the treatment
was lower for those taking probiotics (RR 0.77, 95% confidence interval (CI) 0.63 to 0.93; 16 trials; 2961 participants; number needed
to treat for an additional beneficial outcome (NNTB) = 10; moderate-certainty evidence).
Post hoc subgroup analysis found that among children not prone to otitis media, a lower proportion of children receiving probiotics
experienced AOM (RR 0.64, 95% CI 0.49 to 0.84; 11 trials; 2227 participants; NNTB = 9; moderate-certainty evidence). However,
among children who were otitis prone, there was no difference between probiotic and comparator groups (RR 0.97, 95% CI 0.85 to
1.11; 5 trials; 734 participants; high-certainty evidence). The test for subgroup differences was significant (P = 0.007).
None of the included trials reported on the severity of AOM.
The proportion of children experiencing adverse events did not differ between the probiotic and comparator groups (OR 1.54, 95%
CI 0.60 to 3.94; 4 trials; 395 participants; low-certainty evidence).
Probiotics decreased the proportion of children taking antibiotics for any infection (RR 0.66, 95% CI 0.51 to 0.86; 8 trials; 1768
participants; NNTB = 8; moderate-certainty evidence). Test for subgroup differences (use of antibiotic specifically for AOM, use of
antibiotic for infections other than AOM) was not significant.
There was no difference in the mean number of school days lost (MD −0.95, 95% CI −2.47 to 0.57; 5 trials; 1280 participants;
moderate-certainty evidence). There was no difference between groups in the level of compliance in taking the intervention (RR 1.02,
95% CI 0.99 to 1.05; 5 trials; 990 participants).
Probiotics decreased the proportion of children having other infections (RR 0.75, 95% CI 0.65 to 0.87; 11 trials; 3610 participants;
NNTB = 12; moderate-certainty evidence). Test for subgroup differences (acute respiratory infections, gastrointestinal infections) was
not significant.
Probiotic strains trialled and their dose, frequency, and duration of administration varied considerably across studies, which likely
contributed to the substantial levels of heterogeneity. Sensitivity testing of funnel plots did not reveal publication bias.
Authors’ conclusions
Probiotics may prevent AOM in children not prone to AOM, but the inconsistency of the subgroup analyses suggests caution in
interpreting these results. Probiotics decreased the proportion of children taking antibiotics for any infection. The proportion of children
experiencing adverse events did not differ between the probiotic and comparator groups. The optimal strain, duration, frequency, and
timing of probiotic administration still needs to be established.
P L A I N L A N G U A G E S U M M A R Y
Probiotics (’healthy bacteria’) for preventing acute middle ear infection in children
Review question
Does taking probiotics (‘healthy bacteria’) prevent children from getting acute middle ear infections?
Background
Acute middle ear infection is very common in childhood. It is caused by bacteria that travel from the upper part of the throat, through
canals (called Eustachian tubes), to the middle ear. Symptoms include fever, earache, and occasionally the eardrum may perforate,
discharging pus into the ear canal.
Antibiotics are often prescribed for acutemiddle ear infection, although they have only amodest effect on reducing symptoms.Moreover,
excessive antibiotic use leads to antibiotic resistance, making them less effective for these and other infections. Consequently, preventing
acute middle ear infection is highly desirable.
Probiotics are often sold as tablets or powders, as a food ingredient (e.g. in yogurt), and even sprayed directly into the throat. However,
it is not yet clear whether they prevent acute middle ear infection. We analysed the scientific evidence to answer this question.
Study characteristics and searches
We searched and identified 17 randomised controlled trials (studies in which participants are assigned to one of two or more treatment
groups using a random method), published before October 2018. All were conducted in Europe, and collectively included 3488
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children. Twelve trials included children who were not prone to acute middle ear infections, whilst five trials included children who
were prone to such infections.
Key results
One-third fewer children not prone to acute middle ear infection who took probiotics experienced acute middle ear infections compared
to children not taking probiotics. However, probiotics may not benefit children prone to acute middle ear infection. Taking probiotics
did not impact on the number of days of school that children missed. None of the studies reported on the impact of probiotics on the
severity of acute middle ear infection. There was no difference between the group taking probiotics and the group not taking probiotics
in the number of children experiencing adverse events (harms).
Quality of the evidence
The quality (or certainty) of the evidence was generally moderate (meaning that further research may change our estimates) or high
(further research is unlikely to change our estimates). However, the trials differed in terms of types of probiotics evaluated, how often
and for how long they were taken, and how the trial results were reported.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Probiotic compared to placebo for preventing acute otitis media in children
Patient or population: children up to age 18 years
Setting: community, primary care, and secondary care
Intervention: any probiot ic, delivered by any means
Comparison: comparator
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with probiotic
Proport ion of children
with AOM (overall)
Study populat ion RR 0.77
(0.63 to 0.93)
2961
(16 RCTs)
⊕⊕⊕©
MODERATE1
We conducted a post
hoc sensit ivity analysis
by health status (chil-
dren prone to AOM ver-
sus children not prone
to AOM). The test for
subgroup dif ferences
was signif icant (P = 0.
007). The follow-up du-
rat ion ranged f rom 20
days to 2 years
390 per 1000 300 per 1000
(246 to 362)
Proport ion of children
with AOM:
children not prone to
AOM
Study populat ion RR 0.64
(0.49 to 0.84)
2227
(11 RCTs)
⊕⊕⊕©
MODERATE2
The follow-up durat ion
ranged f rom 20 days to
2 years.295 per 1000 189 per 1000
(145 to 248)
Proport ion of children
with AOM:
children prone to AOM
Study populat ion RR 0.97
(0.85 to 1.11)
734
(5 RCTs)
⊕⊕⊕⊕
HIGH
The follow-up durat ion
ranged f rom 20 days to
2 years.660 per 1000 641 per 1000
(561 to 733)
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Severity of AOM No data No data No data No data N/ A None of the included
studies reported on this
outcome.
Adverse events Study populat ion OR 1.54
(0.60 to 3.94)
395
(4 RCTs)
⊕⊕©©
LOW3
The follow-up durat ion
ranged f rom 20 days to
2 years.186 per 1000 260 per 1000
(121 to 474)
Time of f school for
child
-- MD −0.95 days
(−2.47 to 0.57)
-- 1280
(5 RCTs)
⊕⊕⊕©
MODERATE4
The follow-up durat ion
ranged f rom 20 days
to 2 years. The me-
dian of trial means
for the probiot ic group
was 4.45 days of ab-
sence; the median of
trial means for the com-
parator group was 5.8
days of absence
Dif ference in the use of
ant ibiot ics
Study populat ion RR 0.66
(0.51 to 0.86)
1768
(8 RCTs)
⊕⊕⊕©
MODERATE5
The follow-up durat ion
ranged f rom 20 days to
2 years.397 per 1000 262 per 1000
(203 to 342)
Dif ference in proport ion
of children with other
infect ions
Study populat ion RR 0.75
(0.65 to 0.87)
3610
(11 RCTs)
⊕⊕⊕©
MODERATE6
The follow-up durat ion
ranged f rom 20 days to
2 years.363 per 1000 272 per 1000
(236 to 316)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
AOM: acute ot it is media; CI: conf idence interval; MD: mean dif ference; N/A: not applicable; OR: odds rat io; RCT : randomised controlled trial; RR: risk rat io
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GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for substant ial heterogeneity (72%).
2Downgraded one level for moderate/ substant ial heterogeneity (59%).
3Downgraded two levels for imprecision, wide conf idence intervals, and small number of part icipants.
4Downgraded one level for moderate heterogeneity (54%).
5Downgraded one level for substant ial heterogeneity (70%).
6Downgraded one level for substant ial heterogeneity (64%).
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B A C K G R O U N D
Description of the condition
Acute otitis media (AOM) is one of the most common childhood
infections. It is characterised by effusion of the middle ear and
rapid onset of symptoms such as fever, malaise, ear pain, and,
on occasion, otorrhoea (discharge from the ear) (AAP 2013). Al-
though AOMhas lowmortality, it has a high disease burden (Stool
1989); by two years of age, 70% of children have had at least one
episode of AOM, and 20% to 30% of children have experienced
three or more episodes (Hatakka 2007b). Globally, the incidence
rate (new episodes of AOM per hundred people per year) is esti-
mated at 10.85% (the equivalent of 709 million cases of AOMan-
nually); the incidence rate varies, from a low of 3.64% in Central
Europe to 43.37% in central sub-Saharan Africa (Monasta 2012).
Clinical care guidelines for treatment of AOMvary internationally.
For mild-moderate cases, ’watchful waiting’ has now been adopted
in many high-income countries, although this remains infrequent
in low-income countries (Tamir 2017). Most guidelines recom-
mend amoxicillin as first-line treatment, with some exceptions:
amoxicillin-clavulanate in some high-income countries, penicillin
V in Scandinavian countries, whilst other first-line treatments
in low-income countries include trimethoprim-sulphamethoxa-
zole, cephalexin, cloxacillin, and others (Tamir 2017). Accord-
ingly, AOM is one of the main reasons given for prescribing an-
tibiotics in children (Hendley 2002). However, the rates of an-
tibiotic prescription for AOM vary internationally, from 56% of
consultations for AOM in the Netherlands (Akkerman 2005), to
89% to 95% in Australia and North America, respectively (Froom
2001; McCullough 2017). Antibiotic use leads to antibiotic re-
sistance, therefore there is increased interest in identifying novel
means of preventing AOM, especially since randomised clinical
trials of pneumococcal and influenza vaccines have demonstrated
limited protective efficacy against AOM (Cohen 2013b; Dagan
2016; Fortanier 2014; Hatakka 2007b; Jefferson 2018; Niittynen
2012).
Description of the intervention
TheWorldHealthOrganization (WHO) defines probiotics as live
micro-organisms that confer a health benefit on the host when
administered in adequate amounts (FAO-WHO 2006). Micro-
organisms used as probiotics include: Lactobacillus (e.g. L aci-
dophilus, L fermentum), Bifidobacterium (e.g. B bifidum, B lactis),
Streptococcus (e.g. S thermophiles) species, and Saccharomyces (e.g.
S boulardii) species (Niittynen 2012). Probiotics are available in
multiple forms: as tablets or powders or liquid drops (regulated
as dietary supplements), as a food ingredient (e.g. yogurt or ke-
fir) (Wang 2016), or directly applied by spray to the throat (Roos
2001b). While probiotics are not currently routinely used in clini-
cal practice, they can be used by adults and children (Wang 2016),
and are not generally believed to have harmful effects in healthy,
immunocompetent people (Marteau 2002).
How the intervention might work
Acute otitis media is thought to be caused by pathogenic bacteria
entering the middle ear cleft from the nasopharynx via the Eu-
stachian tubes. Probiotics may restore the balance of the normal
microbiota (Hatakka 2007b), although the mechanism for this is
unclear (Hao 2015); they may stabilise gut microbiota; maintain
epithelial cell barrier function; modulate immune function; com-
pete with pathogens for nutrients or adhesion sites on epithelial
cell surfaces; produce bacteriocins or other inhibitory substances
(Hao 2015; Hatakka 2007b; Niittynen 2012).
Why it is important to do this review
Concern about antibiotic use leading to increased antibiotic re-
sistance has created interest in alternative managements (O’Neill
2014), which include probiotics (Hatakka 2007b). Cochrane Re-
views have investigated other interventions for the prevention of
otitis media, including xylitol (Azarpazhooh 2016), pneumococ-
cal conjugate vaccines (Fortanier 2014), and influenza vaccines
(Norhayati 2017). Another Cochrane Review that addressed pro-
biotics to prevent acute respiratory tract infections did not include
trials with AOM on the grounds that otitis-prone children may
have immunodeficiencies (Hao 2015).
O B J E C T I V E S
To assess the effects of probiotics to prevent the occurrence and
reduce the severity of acute otitis media in children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), irrespective of study design
(e.g. cluster, parallel, cross-over) and publication type (full text,
abstract only, unpublished data).
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Types of participants
Children (aged up to 18 years).
We excluded children with the following comorbidities or char-
acteristics: chromosomal and genetic disorders; craniofacial ab-
normalities, including cleft palate; those taking systemic corticos-
teroids or with immune deficiency status; and those with cystic
fibrosis or primary ciliary dyskinesia.
Types of interventions
We included trials comparing probiotics with placebo or usual care
or no probiotic. The probiotics could be of any composition (e.g.
powder, drink, spray). Any co-intervention (including antibiotics)
applied to both the intervention and control groups could be used.
Types of outcome measures
Primary outcomes
1. Proportion of children with AOM (in each group) (i.e. the
number of children experiencing one or more episodes of AOM
during the treatment).
2. Severity of AOM.
3. Adverse events (e.g. gastrointestinal side effects).
Secondary outcomes
1. Median duration of AOM episodes (days).
2. Difference in the use of antibiotics (e.g. dose, duration).
3. Time off school (for the child) (e.g. in days or hours).
4. Time off work (for the parent or carer) (e.g. in days or
hours).
5. Difference between groups in hearing loss, if AOM occurs.
6. Serous/secretory otitis media.
7. Difference in referrals to a specialist (e.g. for glue ear).
8. Difference in other infections (respiratory and
gastrointestinal).
9. Compliance with taking probiotics (e.g. measured by pill
count or weight of the spray bottle).
10. Quality of life measures (using any validated quality of life
measure).
11. Difference in use of other treatments (e.g. differences in
dosage of analgesics, decongestants).
Search methods for identification of studies
Electronic searches
We searched the following bibliographic databases:
1. Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 9, September), which includes the
Cochrane Acute Respiratory Infections Group Specialised
Register, in the Cochrane Library (searched 4 October 2018);
2. PubMed (1946 to 4 October 2018);
3. Embase Elsevier (1947 to 4 October 2018);
4. CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature, 1982 to 4 October 2018);
5. LILACS (Latin American and Caribbean Health Science
Information database, 1982 to 4 October 2018); and
6. Web of Science (1900 to 4 October 2018).
We searched the following trial registries:
1. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov) (searched 10 October
2018); and
2. World Health Organization International Clinical Trials
Registry Platform ( WHO ICTRP) ( apps.who.int/trialsearch/)
(searched 10 October 2018).
We used the search strategies described in Appendix 1 to search
the bibliographic databases. Where appropriate, these were com-
bined with the Cochrane Highly Sensitive Search Strategy for ran-
domised trials: sensitivity and precision-maximising version (2008
revision) (Lefebvre 2011). We did not impose any language, pub-
lication date, or publication status restrictions.
We used the search strategies described in Appendix 2 to search
ClinicalTrials.gov and the WHO ICTRP to identify published
registered trials, as well as ongoing trials.
We conducted a backwards (cited) and forwards (citing) citation
analyses on all included trials inWeb of Science (28 August 2018).
As we identified no additional trials, we did not carry out the use
of the similar article feature in PubMed and the shared citation
matcher in Web of Science.
Searching other resources
We contacted experts in the field to identify additional unpub-
lished materials, however as no relevant unpublished completed
trials were identified, we did not need to contact trial investigators
for unpublished data.
Data collection and analysis
Selection of studies
Two review authors (AMS and JC, AMS and FI, or AMS and
BJ) independently screened the titles and abstracts identified as
a result of the search for potentially relevant trials. We retrieved
the full-text study reports/publication of all studies deemed po-
tentially relevant, and two review authors (AMS and JC, AMS
and FI, or AMS and BJ) independently screened the full texts and
identified trials for inclusion, and identified and recorded reasons
for exclusion of the ineligible trials. Any disagreements were re-
solved through discussion or by consulting a third review (CDM)
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author when necessary.We identified and excluded duplicates and
collated multiple reports of the same study so that each study,
rather than each report, was the unit of interest in the review. We
recorded the selection process in sufficient detail to complete a
PRISMA flow diagram and Characteristics of excluded studies ta-
ble (Moher 2009). We did not impose any language restrictions.
Data extraction and management
We used a data collection form for study characteristics and out-
come data that had been piloted on two trials in the review. Two
review authors (AMS and FI, or AMS and BJ) independently ex-
tracted the following study characteristics from the included trials.
1. Methods: study location, study design, study objective,
study duration.
2. Participants: N, type of participants, mean age, age range,
gender, comorbidities, number of previous episodes of otitis
media, diagnostic criteria.
3. Interventions: probiotic type, duration, dose, comparison,
other permitted interventions (e.g. concomitant analgesics,
decongestants), other prohibited interventions (e.g. analgesics,
decongestants).
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
We noted in the Characteristics of included studies table if out-
come data were not reported in a useable way. Any disagreements
were resolved by consensus or by involving a third review author
(CDM). One review author (AMS) transferred data into the Re-
view Manager 5 file (RevMan 2014). We double-checked that
data were entered correctly by comparing the data presented in the
systematic review with the study reports. A second review author
(CDM) also conducted a spot-check of study characteristics for
accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (AMS and FI, or AMS and BJ) independently
assessed risk of bias for each study using the criteria outlined in
the Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2011). Any disagreements were resolved by discussion or
by involving another review author (CDM). We assessed risk of
bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear, and
provided a quote from the study report together with a justification
for our judgement in the ’Risk of bias’ table. We summarised
the ’Risk of bias’ judgements across different trials for each of
the domains listed. When considering treatment effects, we took
into account the risk of bias for the trials that contributed to that
outcome.
Assessment of bias in conducting the systematic
review
We conducted the review according to our published protocol (
Scott 2018), and reported any deviations from it in theDifferences
between protocol and review section of the review.
Measures of treatment effect
One review author (AMS) entered the outcome data for each study
into the data tables in ReviewManager 5 to calculate the treatment
effects (RevMan 2014). We analysed dichotomous data as either
risk ratio (RR) or odds ratios (OR) and continuous data as mean
differences (MD).
We calculated the number needed to treat for an additional ben-
eficial outcome (NNTB) in the following manner: NNTB = 1/
ARR, where AAR = absolute risk reduction, that is the absolute
difference between the event rate in the untreated (comparator)
and treated (probiotic) groups.
We undertook meta-analyses only where this was meaningful, that
is if the treatments, participants, and the underlying clinical ques-
tion were similar enough for pooling to make sense. If meta-anal-
ysis was possible, we used a random-effects model due to high
heterogeneity of the included trials.
Unit of analysis issues
We used the participant as the unit of analysis; one cluster-RCT
met our inclusion criteria (Stecksen-Blicks 2009), but it reported
individual data, permitting the use of participant as the unit of
analysis. Nocerino 2017 was a three-armed trial with two probi-
otics arms. We combined the probiotics arms to form one inter-
vention group for the meta-analysis.
Dealing with missing data
We intended to contact investigators or study sponsors to verify
key study characteristics and to obtain missing numerical outcome
data where possible (e.g. when a study was identified as abstract
only), however we included no incomplete or abstract-only trials
in the review.
Where outcome data for standard deviations were missing, we
calculated them from 95% confidence intervals (where available)
according to the methods described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), or from the
range data (Hozo 2005).
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Assessment of heterogeneity
Weused the I2 statistic tomeasure heterogeneity amongst the trials
in each analysis. If we identified substantial heterogeneity and there
were sufficient data, we reported the heterogeneity and explored
possible causes for it by subgroup analysis (e.g. see Analyses 1.1.1,
1.1.2, 1.1.3). We considered an I2 statistic value of 0% to 40% as
low heterogeneity; 41% to 60% as moderate heterogeneity; 61%
to 90% as substantial heterogeneity; and over 91% as considerable
heterogeneity (Higgins 2011).
Assessment of reporting biases
As we were able to pool more than 10 trials, we created a funnel
plot to explore possible small-study and publication bias.
Data synthesis
We pooled data from trials we judged to be clinically homoge-
neous using Review Manager 5 (RevMan 2014). Where three or
more trials provided useable data in any single comparison, we
performed a meta-analysis. We had expected sizeable heterogene-
ity in terms of populations, probiotics studied, etc., which mate-
rialised, therefore we used the random-effects model. Where the
volume of evidence was insufficient to perform a meta-analysis,
we reported outcomes in a narrative format.
GRADE and ’Summary of findings’ table
We created a ’Summary of findings’ table using the following out-
comes: proportion of children with AOM; proportion of children
with AOM among children not prone to AOM; proportion of
children with AOM among children prone to AOM; severity of
AOM; adverse events; time off school; antibiotic use; and propor-
tion of children with other infections. We used the five GRADE
considerations (study limitations, consistency of effect, impreci-
sion, indirectness, and publication bias) to assess the quality (cer-
tainty) of a body of evidence as it related to the trials that con-
tributed data to the meta-analyses for the prespecified outcomes
(Atkins 2004). We used the methods and recommendations de-
scribed in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), employing
GRADEpro GDT software (GRADEpro GDT 2015). We justi-
fied all decisions to down- or upgrade the quality (certainty) of
studies using footnotes, and made comments to aid the reader’s
understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We conducted the following subgroup analyses:
1. proportion of children with AOM by child’s health status
(AOM-prone versus not);
2. proportion of children with AOM by strain of probiotic
(Lactobacillus-containing versus Streptococcus-containing);
3. proportion of children using antibiotics (use for AOM
versus use for infections other than AOM); and
4. proportion of children with other infections (acute
respiratory infections versus gastrointestinal infections).
We used the Chi2 test to test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We did not conduct any sensitivity analyses, as only a single in-
cluded study had two domains rated as at high risk of bias (Di
Pierro 2016).
R E S U L T S
Description of studies
Results of the search
We searched six databases (see Electronic searches) and retrieved
1633 records. A backwards (screening of the reference lists) and
forwards citation analysis, undertaken in Web of Science on our
initial list of included trials, retrieved 952 records for screening,
for a total of 2585 records for screening. Our search of two clinical
trial registers identified 25 further trials.
After removal of duplicates (from both the search and the citation
analysis), a total of 1700 records remained for screening. We ex-
cluded 1612 records based on title and abstract. We obtained the
full texts of the remaining 88 records. We excluded 69 trials (see
Characteristics of excluded studies table). From the 25 clinical trial
register results, we identified nine ongoing trials. No trials were
awaiting classification.
We included 17 trials reported in 19 references (see Characteristics
of included studies table). For a detailed description of our screen-
ing process, see the study flow diagram in Figure 1. All included
trials came from the original search; the citation analysis and search
of trial registries identified no additional trials.
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Figure 1. Study flow diagram.
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Included studies
We included 19 references that reported on 17 randomised clinical
trials. Two trials, Maldonado 2012; Taipale 2011, also reported
two- or three-year follow-up data, respectively (Maldonado 2015;
Taipale 2016).
Study design
Sixteen RCTs had a two-arm parallel design, and one RCT had
a three-arm parallel design (Nocerino 2017). Sixteen RCTs ran-
domised by individual, whilst one RCT was a cluster-randomised
study, but also reported numbers for individuals (Stecksen-Blicks
2009).
Participants
All 17 included RCTs involved children. The mean (or median
where reported instead) age ranged from one-month-old infants,
in Taipale 2011, to 17.5-year-olds, in Di Nardo 2014. The trials
included a total of 3488 participants, all of whom were children
(aged < 18 years old).
Five RCTs reported on children prone to otitis (Cohen 2013a;
Hatakka 2007a; Marchisio 2015; Roos 2001a; Tano 2002), whilst
the remaining RCTs reported on children not prone to otitis. The
definition of ’otitis-prone’ was not clear and may have involved a
subjective element.
All of the included trials were performed in Europe: two in
Croatia (Hojsak 2010a; Hojsak 2016); four in Finland (Hatakka
2001a; Hatakka 2007a; Rautava 2009; Taipale 2011/Taipale
2016); one in France (Cohen 2013a); five in Italy (Corsello 2017;
Di Nardo 2014; Di Pierro 2016; Marchisio 2015; Nocerino
2017); one in Russia (Karpova 2015); one in Spain (Maldonado
2012/Maldonado 2015); and three in Sweden (Roos 2001a;
Stecksen-Blicks 2009; Tano 2002).
Interventions
Two trials included synbiotics, that is a combination of prebi-
otic and probiotic (Cohen 2013a; Maldonado 2012/Maldonado
2015); the remaining trials tested probiotics consisting of single
or multiple bacterial strains. Eleven RCTs evaluated Lactobacillus-
containing probiotics (Corsello 2017; Di Nardo 2014; Hatakka
2001a; Hatakka 2007a; Hojsak 2010a; Hojsak 2016; Maldonado
2012/Maldonado 2015; Nocerino 2017; Rautava 2009; Stecksen-
Blicks 2009; Taipale 2011/Taipale 2016); six RCTs evaluated
Streptococcus-containing probiotics (Cohen 2013a; Di Pierro
2016; Karpova 2015; Marchisio 2015; Roos 2001a; Tano 2002).
The probiotics were administered as powder or drops dissolved
in a liquid (e.g. milk or water) in nine RCTs (Cohen 2013a;
Corsello 2017; Di Nardo 2014; Hatakka 2001a; Hojsak 2010a;
Hojsak 2016; Maldonado 2012/Maldonado 2015; Nocerino
2017; Stecksen-Blicks 2009); as capsule or tablet in four RCTs (Di
Pierro 2016;Hatakka 2007a; Rautava 2009; Taipale 2011/Taipale
2016); and as a spray in four RCTs (Karpova 2015; Marchisio
2015; Roos 2001a; Tano 2002).
Duration of administration of the probiotic ranged from 20 days,
in Roos 2001a, to two years, in Taipale 2016.
Two-arm trials compared probiotic to placebo (15 RCTs) or to
untreated group (one RCT; Di Pierro 2016); one three-arm trial
compared two probiotic groups to placebo (Nocerino 2017).
Outcome measures
Primary outcomes
Outcomemeasures were reported in a variety of ways. The primary
outcome, proportion of children with AOM, was reported by all
17 trials, most frequently as the number of children with AOM
in each group (Cohen 2013a; Corsello 2017; Di Nardo 2014;
Hatakka 2001a; Hatakka 2007a; Hojsak 2010a; Hojsak 2016;
Karpova 2015; Marchisio 2015; Nocerino 2017; Rautava 2009;
Roos 2001a; Taipale 2011/Taipale 2016; Tano 2002), although
some trials reported the number of AOM events in each group,
Maldonado 2012/Maldonado 2015, or the mean number of days
with otitis media in each group (Stecksen-Blicks 2009).
No trials reported on severity of AOM.
Fourteen RCTs reported on adverse events, most often narratively.
Eight trials stated that no adverse events were reported (Corsello
2017; Di Pierro 2016; Hatakka 2001a; Hojsak 2010a; Hojsak
2016; Maldonado 2012; Nocerino 2017; Stecksen-Blicks 2009);
two trials reported the number of events in each group (Cohen
2013a;Tano 2002); and four trials reported the number of children
with events in each group (Marchisio 2015; Rautava 2009; Roos
2001a; Taipale 2011/Taipale 2016).
Secondary outcomes
Only one study reported median duration of AOM episodes (
Hatakka 2007a), which reported on the median duration and
interquartile range of the AOM episodes in each group.
Five trials reported on difference between groups in the use of
antibiotics specifically for AOM (Cohen 2013a; Hojsak 2010a;
Karpova 2015;Marchisio 2015;Roos 2001a), either as the number
of antibiotic courses in each group, Cohen 2013a, or as the num-
ber of children treated with antibiotics for AOM in each group
(Hojsak 2010a; Karpova 2015; Marchisio 2015; Roos 2001a).
Nine trials reported on difference in the use of antibiotics more
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generally, for any infection, as the number of antimicrobial treat-
ments or prescriptions per child in each group (Hatakka 2007a;
Hojsak 2016; Maldonado 2012); the number of children who re-
ceived antibiotics in each group (Corsello 2017; Hatakka 2001a;
Nocerino 2017; Rautava 2009; Taipale 2011); or the mean num-
ber of days with antibiotic treatment (Stecksen-Blicks 2009).
Five trials reported on time off school for the child, as the mean
number of days of absence from school or day care (Corsello 2017;
Hatakka 2001a; Hojsak 2010a; Hojsak 2016; Stecksen-Blicks
2009).
One study reported on time off work for the parent or carer (
Corsello 2017), as the mean number of lost days of work for
parents.
None of the included trials reported on difference between groups
in hearing loss if AOM occurs.
Two trials reported on serous/secretory otitis media (Rautava
2009; Roos 2001a). One study reported on the number of chil-
dren in each group with secretory otitis media at their last visit
(Roos 2001a), and one reported on the number of children in each
group requiring tympanostomies to prevent recurrent AOM or to
treat secretory otitis media (Rautava 2009).
None of the included trials reported on difference in referrals to
specialists.
Difference in other infections was reported in terms of reduction
in acute respiratory infections and reductions in gastrointestinal
(GI) infections. Fifteen trials reported on difference in respiratory
infections, as: mean number of respiratory infections or episodes
in each group (Cohen 2013a; Di Nardo 2014; Hatakka 2007a;
Maldonado 2012/Maldonado 2015; Tano 2002); number of chil-
dren with respiratory infections (Corsello 2017; Di Pierro 2016;
Hatakka 2001a; Hojsak 2010a; Hojsak 2016; Karpova 2015;
Nocerino 2017; Rautava 2009; Taipale 2011/Taipale 2016); or the
mean number of days with respiratory symptoms (Stecksen-Blicks
2009). Eleven trials reported on difference in GI infections, as:
the number of children with GI infections in each group (Cohen
2013a; Corsello 2017; Hojsak 2010a; Hojsak 2016; Nocerino
2017; Rautava 2009; Taipale 2011/Taipale 2016); the number
of GI infections in each group (Di Nardo 2014; Maldonado
2012/Maldonado 2015); or the mean number of days with GI
symptoms (Hatakka 2001a; Stecksen-Blicks 2009).
Thirteen trials reported on compliance with taking probiotics,
as: the number of capsules eaten (Hatakka 2007a); the number
of children complying or not complying with treatment (Cohen
2013a; Hojsak 2010a; Hojsak 2016; Marchisio 2015; Taipale
2011); the percentage of days duringwhich consumption exceeded
a prespecified amount (Hatakka 2001a); or narratively, for example
by stating that the compliance was “good” or the treatment was
“well-received” (Corsello 2017;Di Pierro 2016;Maldonado 2012;
Nocerino 2017; Stecksen-Blicks 2009; Taipale 2011).
One study reported on quality of life measures (Hatakka 2001a),
which reported a mean total symptom score for both groups (mea-
suring the overall burden of symptoms on a scale of 0 to 9).
Three trials reported on difference in the use of other treatments
(Corsello 2017; Karpova 2015; Nocerino 2017), as the number of
children consuming corticosteroids and antipyretics, in Corsello
2017 and Nocerino 2017, or the number of prescriptions for cor-
ticosteroids, in Karpova 2015, in each group.
Study funding sources
Funding sources for the included studies are reported in the
Characteristics of included studies table.
Two studies did not report funding (Di Pierro 2016; Karpova
2015).
Eight studies were funded at least partially (either financially or
in-kind, e.g. by providing formula or probiotic) by manufacturers
of probiotic or formula, but the role of the sponsor in the design,
analysis, interpretation, or write-up of the study was not stated
(Cohen 2013a; Hatakka 2001a; Hatakka 2007a; Hojsak 2016;
Maldonado 2012; Marchisio 2015; Stecksen-Blicks 2009; Tano
2002). Three studies reported funding at least partially (either
financially or in-kind, e.g. by providing formula or probiotic) by
manufacturers of probiotic or formula, and reported at least some
sponsor involvement in study design, analysis, interpretation, or
write-up (Maldonado 2015; Taipale 2011; Taipale 2016).
One study was funded by non-industry funders, but the role of
the sponsor was unclear (Roos 2001a).
Five studies reported funding at least partially by manufacturers
and explicitly stated that the funder had no role in the design,
analysis, interpretation, or write-up of the study (Corsello 2017;
Di Nardo 2014; Hojsak 2010a; Nocerino 2017; Rautava 2009).
Excluded studies
We excluded 70 trials (Figure 1). The reasons for their exclusion
are provided in the Characteristics of excluded studies table.
Risk of bias in included studies
The overall risk of bias of the included trials (Characteristics of
included studies table) is presented graphically in Figure 2 and
Figure 3.
13Probiotics for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sixteen trials clearly described random sequence generation (
Cohen 2013a; Corsello 2017; Di Nardo 2014; Di Pierro 2016;
Hatakka 2001a; Hatakka 2007a; Hojsak 2010a; Hojsak 2016;
Maldonado 2012/Maldonado 2015; Marchisio 2015; Nocerino
2017; Rautava 2009; Roos 2001a; Stecksen-Blicks 2009; Taipale
2011/Taipale 2016; Tano 2002). One study was described as ran-
domised, but themethod of randomisation was not described, and
a table of baseline characteristics to permit evaluation of whether
randomisation worked was not provided (Karpova 2015)
Four trials described allocation concealment (Di Nardo 2014;
Hojsak 2016; Nocerino 2017; Stecksen-Blicks 2009). The re-
maining 13 trials did not describe whether allocation was con-
cealed (Cohen 2013a; Corsello 2017; Di Pierro 2016; Hatakka
2001a;Hatakka 2007a;Hojsak 2010a; Karpova 2015;Maldonado
2012/Maldonado 2015; Marchisio 2015; Rautava 2009; Roos
2001a; Taipale 2011/Taipale 2016; Tano 2002).
Blinding
Fourteen trials were double-blinded (Cohen 2013a; Corsello
2017; Di Nardo 2014; Hatakka 2001a; Hatakka 2007a; Hojsak
2010a; Hojsak 2016; Marchisio 2015; Nocerino 2017; Rautava
2009; Roos 2001a; Stecksen-Blicks 2009; Taipale 2011/Taipale
2016; Tano 2002). One study was double-blinded (Maldonado
2012), but it was not clear whether its three-year follow-up was
also double-blinded (Maldonado 2015). One study did not clearly
report blinding of participants and personnel (Karpova 2015).
One study compared probiotic to no treatment and was thus con-
sidered unlikely to be blinded (Di Pierro 2016).
Blinding of outcome assessor occurred in six trials (Corsello 2017;
Di Nardo 2014; Hojsak 2010a; Hojsak 2016; Nocerino 2017;
Taipale 2011/Taipale 2016). In one study the outcome assessors
were blinded (Maldonado 2012), but it was unclear whether this
was also the case for the three-year follow-up (Maldonado 2015).
Blinding was unclear in the remaining 10 trials (Cohen 2013a;
Di Pierro 2016; Hatakka 2001a; Hatakka 2007a; Karpova 2015;
Marchisio 2015; Rautava 2009; Roos 2001a; Stecksen-Blicks
2009; Tano 2002).
Incomplete outcome data
Sixteen trials reported attrition in both arms with reasons (Cohen
2013a; Di Nardo 2014; Di Pierro 2016; Hatakka 2001a; Hatakka
2007a; Hojsak 2010a; Hojsak 2016; Karpova 2015; Maldonado
2012/Maldonado 2015;Marchisio 2015;Nocerino2017;Rautava
2009; Roos 2001a; Stecksen-Blicks 2009; Taipale 2011/Taipale
2016; Tano 2002). One study reported the attrition for both arms
but did not provide reasons for it (Corsello 2017); however, as the
attrition was less than 20% in both arms, we judged risk of bias
to be low.
15Probiotics for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Selective reporting
We considered whether the trials reported all of the primary
and secondary outcomes specified in their methods sections.
We judged 12 trials as at low risk of bias (all prespecified out-
comes were reported) (Di Nardo 2014; Di Pierro 2016; Hatakka
2001a; Hatakka 2007a; Hojsak 2010a; Hojsak 2016; Maldonado
2012/Maldonado 2015; Nocerino 2017; Rautava 2009; Roos
2001a; Stecksen-Blicks 2009; Taipale 2011/Taipale 2016). We as-
sessed five trials as at unclear risk of bias for this domain either be-
cause one of the outcomeswas unreported (Cohen 2013a;Corsello
2017; Karpova 2015), or because it was not clear which outcomes
were primary or secondary (Marchisio 2015; Tano 2002).
Other potential sources of bias
We judged four trials at low risk of other bias (Corsello 2017; Di
Nardo 2014; Hojsak 2010a; Nocerino 2017). Three trials were
judged at unclear risk of other bias due either to absence of in-
formation about or an unclear statement of authors’ conflicts of
interest (Rautava 2009; Roos 2001a), or failure to report their
funding source (Taipale 2016). We assessed 12 trials as at high
risk of other bias due to authors’ employment with study funder,
undeclared conflict of interest, and unstated role of the funder in
the study design, analysis, interpretation, and manuscript writing
(Cohen 2013a; Di Pierro 2016; Hatakka 2001a; Hatakka 2007a;
Hojsak 2016; Karpova 2015;Maldonado 2012/Maldonado 2015;
Marchisio 2015; Stecksen-Blicks 2009; Taipale 2011; Tano 2002).
Effects of interventions
See: Summary of findings for the main comparison Probiotic
compared to placebo for preventing acute otitis media in children
Primary outcomes
1. Proportion of children with AOM
All 17 RCTs reported on this outcome. Two trials, Maldonado
2012/Maldonado 2015; Stecksen-Blicks 2009, could not be
pooled with the other 15 trials. Maldonado 2012/Maldonado
2015 reported the number of AOM events in each group, rather
than the number of children with AOMevents in each group. The
difference between groups in the number of AOM events was not
significant. Stecksen-Blicks 2009 reported the mean number of
days with otitis media; the difference between groups was signif-
icant and favoured probiotics: 0.5 days (standard deviation (SD)
2.2) in the probiotic group versus 1.0 (SD 2.7) days in the com-
parator group, P = 0.003.
We pooled 16 RCTs in three meta-analyses (Cohen 2013a;
Corsello 2017; Di Nardo 2014; Di Pierro 2016; Hatakka 2001a;
Hatakka 2007a; Hojsak 2010a; Hojsak 2016; Karpova 2015;
Marchisio 2015; Nocerino 2017; Rautava 2009; Roos 2001a;
Taipale 2011; Taipale 2016; Tano 2002).
A meta-analysis of 16 RCTs showed that a smaller proportion of
children taking probiotics experiencedAOM(risk ratio (RR) 0.77,
95% confidence interval (CI) 0.63 to 0.93; P = 0.006; number
needed to treat for an additional beneficial outcome (NNTB) =
10; I2 = 72%; moderate-certainty evidence; Analysis 1.1).
The funnel plot revealed asymmetry (Figure 4). We explored the
asymmetry by removing from the analysis two studies whose stan-
dard error was above 0.5 (Di Nardo 2014; Karpova 2015). Their
removal restored symmetry to the funnel plot, but only slightly
changed the effect estimate (RR 0.78, 95% CI 0.65 to 0.95; I2 =
73%; P = 0.01).
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Figure 4. Funnel plot of comparison: 1 Probiotics versus placebo or usual care, outcome: 1.1 Proportion of
children with AOM (overall).
A meta-analysis subgrouping the trials into those that included
children who were otitis-prone, Cohen 2013a; Hatakka 2007a;
Marchisio 2015; Roos 2001a; Tano 2002, and those that included
children who were not otitis-prone, Corsello 2017; Di Nardo
2014; Di Pierro 2016; Hatakka 2001a; Hojsak 2010a; Hojsak
2016; Karpova 2015; Nocerino 2017; Rautava 2009; Taipale
2011/Taipale 2016, was not pre-planned but was possible due to
sufficient data. The meta-analysis showed no significant difference
between probiotics and comparator for otitis-prone children (RR
0.97, 95% CI 0.85 to 1.11; I2 = 32%; P = 0.64). Children who
were not prone to otitis media, however, benefited from probi-
otics, as a smaller proportion experienced AOM (RR 0.64, 95%
CI 0.49 to 0.84; I2 = 59%; P = 0.001; NNTB = 9; Analysis 1.2;
Summary of findings for the main comparison). The test for sub-
group differences was significant (P = 0.007).
A meta-analysis subgrouping the trials into those that evalu-
ated Lactobacillus-containing probiotics, Corsello 2017; Di Nardo
2014; Hatakka 2001a; Hatakka 2007a; Hojsak 2010a; Hojsak
2016; Nocerino 2017; Rautava 2009; Taipale 2011/Taipale 2016;
Tano 2002, and those that evaluated Streptococcus-containing pro-
biotics, Cohen 2013a; Di Pierro 2016; Karpova 2015; Marchisio
2015; Roos 2001a; Tano 2002, showed that Lactobacillus-contain-
ing probiotics significantly decreased the proportion of children
with AOM (RR 0.72, 95% CI 0.54 to 0.98; I2 = 72%; P = 0.04;
NNTB=13), but this was not the case for Streptococcus-containing
probiotics (RR 0.78, 95% CI 0.60 to 1.02; I2 = 74%; P = 0.07).
The test for subgroup differences was not significant (P = 0.70)
(Analysis 1.3).
2. Severity of AOM
None of the included trials reported on the severity of AOM.
3. Adverse events
Fourteen trials reported on adverse events.
Eight trials reported on adverse events narratively, all stating that
no adverse events were reported (Corsello 2017; Di Pierro 2016;
Hatakka 2001a; Hojsak 2010a; Hojsak 2016; Maldonado 2012;
Nocerino 2017; Stecksen-Blicks 2009).
Two trials reported the number of adverse events in the probi-
otic and comparator groups (Cohen 2013a; Tano 2002). Cohen
2013a reported five adverse events (lack of appetite for milk, re-
gurgitation, dry skin, chronic diarrhoea, and abdominal pain) as
likely to have been related to the study; four were in the probiotic
group and one was in the comparator group, although it was un-
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clear which event occurred in which group. Tano 2002 reported
the following adverse events: rhinitis, cough, rash, nosebleed, and
vomiting. The total number of adverse events in the placebo group
(n = 5) was higher than in the probiotic group (n = 4), P values
were not reported.
Four trials reported on the number of children with adverse
events in each group (Marchisio 2015; Rautava 2009; Roos 2001a;
Taipale 2011/Taipale 2016). As data from Taipale 2016 reiterate
data from Taipale 2011, this study was not pooled in order to
avoid double-counting; the remaining trials were pooled. The re-
sults showed no significant difference between groups in the num-
ber of children with adverse events (odds ratio (OR) 1.54, 95%
CI 0.60 to 3.94; P = 0.37; low-certainty evidence; Analysis 1.4;
Summary of findings for the main comparison).
Secondary outcomes
1. Median duration of AOM episodes
One trial reported on the median duration of AOM episodes
(Hatakka 2007a), finding that the median duration of an AOM
episode among children taking probiotics was 5.6 days (interquar-
tile range (IQR) 3.5 to 9.4 days), whilst among children taking
placebo it was 6.0 days (IQR 4.0 to 10.5 days). The difference
between groups was not significant.
2. Difference in the use of antibiotics
Eight trials reported data that could be pooled (Corsello 2017;
Hatakka 2001a; Hojsak 2016; Karpova 2015; Marchisio 2015;
Nocerino 2017; Rautava 2009; Taipale 2011); the pooled data
overall favoured the probiotic group (RR 0.66, 95% CI 0.51
to 0.86; P = 0.002; NNTB = 8; I2 = 70%; moderate-cer-
tainty evidence; Analysis 1.5; Summary of findings for the main
comparison).
There were sufficient data to perform subgroup analyses that were
not prespecified in the protocol: use of antibiotics for AOM specif-
ically, and use of antibiotics more generally. However, the test for
subgroup differences was not significant (P = 0.96).
Difference between groups in the use of antibiotics was reported
specifically for AOM as either the number of antibiotic courses
for AOM in each group, in Cohen 2013a, or as the number of
children treated with antibiotics for AOM, in Hojsak 2010a;
Karpova 2015; Marchisio 2015; Roos 2001a. We pooled the data
from the latter studies, excepting the Roos 2001a study, where
antibiotics were part of the intervention in both groups. Pooled
data showed no difference between groups (RR 0.63, 95%CI 0.30
to 1.32; P = 0.22; I2 = 58%; moderate-certainty evidence). Data
from Cohen 2013a were not pooled but showed no significant
difference between groups in the number of antibiotic courses (242
courses per 112 children in the probiotic group versus 226 courses
per 112 children in the comparator group; P = 0.45; Analysis 1.5)
Nine trials reported the difference in the use of antibiotics for any
infection (other than AOM), as follows: the number of antimicro-
bial treatments or prescriptions per child (Hatakka 2007a; Hojsak
2016;Maldonado 2012); the number of childrenwho received an-
tibiotics in each group (Corsello 2017; Hatakka 2001a; Nocerino
2017; Rautava 2009; Taipale 2011); or the mean number of days
with antibiotic treatment in each group (Stecksen-Blicks 2009).
Data on the number of children receiving antibiotics in each group
were pooled, and favoured the probiotic group (RR 0.65, 95% CI
0.45 to 0.92; P = 0.01; NNTB = 6; I2 = 77%; moderate-certainty
evidence; Analysis 1.5). The studies that could not be pooled all
showed no significant difference in the use of antibiotics between
probiotic and comparator groups (Hatakka 2007a; Hojsak 2016;
Maldonado 2012; Stecksen-Blicks 2009).
However, it is worth noting that effect size estimates for the two
subgroups (use of antibiotic for AOM, use of antibiotic for infec-
tions other than AOM) are very similar, so it is possible that the
non-significant finding for the former is due to underpowering.
3. Time off school for the child
Five trials reported on the mean number of days of children’s
absence from school or day care in each group (Corsello 2017;
Hatakka 2001a; Hojsak 2010a; Hojsak 2016; Stecksen-Blicks
2009). Pooled data showed the difference between groups was not
significant (mean difference (MD)−0.95 days, 95% CI−2.47 to
0.57; P = 0.22; I2 = 54%; Analysis 1.6).
4. Time off work for the parent or carer
One trial reported on time off work for the child’s parent or carer
(Corsello 2017). The mean number of lost workdays was signifi-
cantly lower in the probiotic group (0.6 days, 95% CI 0.2 to 1.0)
than in the comparator group (3.3 days, 95% CI 1.1 to 5.5).
5. Difference between groups in hearing loss, if AOM occurs
None of the included trials reported on the difference between
groups in hearing loss.
6. Serous/secretory otitis media
Two trials reported on this outcome, one directly, Roos 2001a,
and one indirectly, Rautava 2009.
Roos 2001a reported on the number of childrenwith secretory oti-
tis media at last study visit, finding that fewer children in the pro-
biotic group had serous otitis media (19% versus 27%). Rautava
2009 reported on rates of tympanostomy that were performed to
either prevent recurrent AOM or to treat secretory otitis media:
0% of children in the probiotic group and 10% in the comparator
group required tympanostomy, but the difference was not signifi-
cant (P = 0.07).
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7. Difference in referrals to a specialist
None of the included trials reported on referrals to a specialist.
8. Difference in other infections
Overall, a smaller proportion of children in the probiotic group
had infections (RR 0.75, 95% CI 0.65 to 0.87; P < 0.001; NNTB
= 12; I2 = 64%; Analysis 1.7; Summary of findings for the main
comparison).
There were sufficient data to perform the following subgroup anal-
yses not prespecified in the protocol: reduction in acute respiratory
infections and reduction in GI infections.
Fifteen trials reported on difference in acute respiratory infections,
as follows: mean number of days with respiratory symptoms in
each group (Stecksen-Blicks 2009); mean number of respiratory
infections or episodes in each group (Cohen 2013a; Di Nardo
2014; Hatakka 2007a; Maldonado 2012/Maldonado 2015; Tano
2002); or number of children with respiratory infections in each
group (Corsello 2017; Di Pierro 2016; Hatakka 2001a; Hojsak
2010a; Hojsak 2016; Karpova 2015; Nocerino 2017; Rautava
2009; Taipale 2011/Taipale 2016).
The mean number of days with respiratory symptoms was lower
in the comparator group than in the probiotic group (9.8 days
versus 15.4 days, respectively) (Stecksen-Blicks 2009).
The mean number of respiratory infections or episodes in each
groupwas either not significantly different between groups, Cohen
2013a; Hatakka 2007a; Maldonado 2015; Tano 2002, or signif-
icantly lower among children in the probiotic group, Di Nardo
2014; Maldonado 2012.
Data for the number of childrenwith respiratory infections in each
group were pooled, showing that a smaller proportion of children
in the probiotic group had respiratory infections (RR 0.74, 95%
CI 0.62 to 0.88; P < 0.001; NNTB = 11; I2 = 70%; moderate-
certainty evidence; Analysis 1.7) (Corsello 2017; Di Pierro 2016;
Hatakka 2001a; Hojsak 2010a; Hojsak 2016; Karpova 2015;
Nocerino 2017; Rautava 2009; Taipale 2011/Taipale 2016).
Eleven trials reported on difference in GI infections, as follows:
mean number of days with GI symptoms in each group (Hatakka
2001a; Stecksen-Blicks 2009); number of GI infections in each
group (Di Nardo 2014; Maldonado 2012/Maldonado 2015); or
number of children with GI infections (Cohen 2013a; Corsello
2017;Hojsak 2010a;Hojsak 2016;Nocerino2017;Rautava 2009;
Taipale 2011/Taipale 2016).
In one trial the mean number of days with GI symptoms did
not differ significantly between groups (Hatakka 2001a), whilst
in another trial, it was lower in the control group (1.1, SD 1.8)
than in the probiotic group (1.7, SD 2.3) (intracluster coefficient
0.16) (Stecksen-Blicks 2009).
In one trial the number of GI infections in each group did not
differ significantly between groups (Di Nardo 2014). In another
trial there were significantly more GI events in the probiotic group
than in the control group (incidence rate decrease 46%, P = 0.032)
(Maldonado 2012), but not in the three-year follow-up (P=0.947)
(Maldonado 2015).
Data for studies that reported the number of children with GI
infections in each group were pooled (Cohen 2013a; Corsello
2017; Hojsak 2010a; Hojsak 2016; Nocerino 2017; Rautava
2009; Taipale 2011/Taipale 2016), showing no difference between
groups in the proportion of children with GI infections (RR 0.78,
95% CI 0.57 to 1.06; P = 0.11; I2 = 61%; moderate-certainty
evidence; Analysis 1.7).
Test for subgroup differences was not significant (P = 0.76).
9. Compliance with taking probiotics
Thirteen trials reported compliance with taking probiotics. Six
trials reported on this outcome narratively, all stating that com-
pliance was “good” or that the treatment was “well-received”
(Corsello 2017; Di Pierro 2016; Maldonado 2012; Nocerino
2017; Stecksen-Blicks 2009; Taipale 2011). One trial reported on
the percentage of capsules consumed (Hatakka 2007a), which was
96% in both groups.One trial reported the percentage of days dur-
ing which consumption exceeded a prespecified amount (Hatakka
2001a), which was 60% in both groups. Five trials reported on the
number of children complying or not complying with treatment
(Cohen 2013a; Hojsak 2010a; Hojsak 2016; Marchisio 2015;
Taipale 2016), permitting the pooling of data. Pooled data showed
no significant difference between groups in compliance (RR 1.02,
95% CI 0.99 to 1.05; P = 0.21; I2 = 0%; Analysis 1.8).
10. Quality of life measures
Hatakka 2001a reported on quality of life using the total symptom
score (defined as a measure of the overall symptom burden, which
consisted of the sum of all of the recorded symptoms ranging from
0 to 9). The difference between groups was not significant, with
a mean unadjusted score of 34 in the probiotic group (95% CI
30 to 39) and 40 in the control group (95% CI 35 to 46), P =
0.10. Mean age-adjusted scores also did not differ significantly:
the mean score was 36 for the probiotic group (95% CI 32 to 40)
and 39 for the control group (95% CI 34 to 44), P = 0.36.
11. Difference in use of other treatments
Three trials reported on the difference between groups in the use of
other treatments (Corsello 2017; Karpova 2015; Nocerino 2017).
Corsello 2017 reported a significantly lower use of antipyretics (P
= 0.044) and corticosteroids (P = 0.027) in the probiotic group
compared to the placebo group.
Nocerino 2017 reported a significantly lower use of antipyretics in
one probiotic group (rice with Lactobacillus paracasei CBA L74, P
= 0.001) and lower use of antipyretics in another probiotic group
(milk with Lactobacillus paracasei CBA L74, P = 0.058) than in
placebo. The study authors also reported a significantly lower use
of corticosteroids in one probiotic group (milk with Lactobacillus
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paracasei, P = 0.001) and lower use of corticosteroids in another
probiotic group (rice with Lactobacillus paracasei, P = 0.07) than
in placebo.
Karpova 2015 reported that 47% children in the probiotic group,
compared to 93% in the control group, had prescriptions of in-
tranasal corticosteroids (however, an inclusion criterion of this
study was children with signs of chronic adenoiditis).
D I S C U S S I O N
Summary of main results
This review suggests that probiotics prevent AOM, the primary
outcome, by a clinically important amount. However, a subgroup
analysis (not planned a priori) suggests that this effect was evident
only in children who were not otitis-prone; the effect was not ob-
served for otitis-prone children (as defined by studies themselves,
and it is worth noting that the definition was not always clear
and may have involved a subjective element). This is consistent
with results from clinical trials of pneumococcal conjugate vac-
cines, which found a modest benefit for those already at low risk
of AOM, but no protective effect for those with established re-
current disease, including otitis-prone children (Fortanier 2014).
These findings may be due to clinical, pathological, and particu-
larly immunological differences between children who are otitis-
prone and those who are not otitis-prone (Pichichero 2016; Xu
2016).
Alternatively, there may be a methodological effect from increased
bias, such as publication bias, of trials of children not prone to
otitis media. Testing for publication bias by funnel plot does not
support this, but statistical methods for determining publication
bias are notoriously insensitive (Higgins 2011).
Another possibility is that any intervention effect is under-re-
ported: diagnosis of AOM is notoriously difficult and frequently
relies upon subjective clinical judgement (Pirozzo 2000). Some
RCTs of interventions for AOM require special training in the di-
agnosis of AOM for participating clinicians, since overdiagnosis of
AOM would decrease the intervention effect (Hoberman 2016).
This is also problematic where allocation concealment and blind-
ing of outcomes are incomplete, which even subconsciously risks
influencing diagnostic behaviour, resulting in a potential misclas-
sification bias.
However, efficacy was supported by some secondary outcomes:
decreased infections other than AOM (for acute respiratory in-
fections if not GI infections) and overall decreased antibiotic use
(although unexpectedly for infections other than AOM, but not
for AOM itself ). Nevertheless, given the considerable variation in
the probiotic strains trialled, their frequency, and duration of ad-
ministration across studies, the optimal regimen is currently un-
clear. Further large and well-conducted RCTs, testing a range of
probiotic strains and administration regimens (frequency, dose,
duration), as well as collecting data on outcomes for which there is
currently very limited evidence (e.g. severity of AOM, duration of
AOM episodes, need for antibiotics, time off work for carer, hear-
ing loss, referrals to specialists, and quality of life) may therefore
help to resolve doubts about the real effectiveness of probiotics.
The pooled results found no consistent increase in adverse effects.
Overall completeness and applicability of
evidence
We searched six distinct databases with no language restriction and
searched trials registers, supplemented by forward- and backward-
searching of cited works. However, we did not contact authors for
additional research, nor did we handsearch conference proceed-
ings, partly because there are no obvious conference candidates for
this.
The volume of evidence varied considerably among the outcomes.
There was sufficient evidence to perform meta-analyses for two
of the primary outcomes (proportion of children with AOM and
adverse events), but none of the included studies reported on the
primary outcome severity of AOM.
The volume of evidence varied for the secondary outcomes. There
was sufficient evidence to perform meta-analyses for four sec-
ondary outcomes (difference in the use of antibiotics, time off
school for the child, difference in other infections, compliance
with taking probiotics). Seven of the secondary outcomes were not
meta-analysable. This was due to variability of reporting (differ-
ence in use of other treatments outcome) or paucity of evidence
(two trials reported on the serous/secretory otitis media outcome;
one trial reported on each of the following outcomes: median du-
ration of AOM episodes, time off work for parent/carer, quality
of life). No trials reported on referrals to specialist or difference in
hearing loss between groups.
Quality of the evidence
We assessed the quality (certainty) of the evidence as moderate for
most of the outcomes reported in the Summary of findings for the
main comparison, including: proportion of children with AOM
overall, proportion of children with AOM among children not
prone to AOM, antibiotic use, and proportion of children with
other infections. We assessed the quality of the evidence for one
outcome - proportion of children with AOMamong children who
were prone to AOM - as high. No studies reported on the severity
of AOM, therefore no quality of evidence rating was assigned. Risk
of bias among the included studies was mostly related to allocation
concealment, blinding of outcomes, and conflicts of interest and
unclear role of funders in the trials.
Potential biases in the review process
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Both clinical heterogeneity (especially from the disparate probi-
otic strains) and statistical heterogeneity confirmed our protocol-
declared use of random-effects model analysis to avoid making in-
appropriate assumptions about the trials testing similar interven-
tions. Heterogeneity was the principal reason for marking down
the certainty of the evidence in theGRADE assessment (Summary
of findings for the main comparison).
Biases could have arisen due to differences between the protocol
and the systematic review (see the Differences between protocol
and review section), in particular from: the broadening of the
population (from children diagnosed with AOM to any children);
omission of three of the prespecified subgroup analyses (one due
to broadening of the population, two due to paucity of evidence);
two subgroup analyses performed due to unanticipated availability
of data (difference in the use of antibiotics, reduction in other
infections). We did not perform sensitivity analysis (as only one
included study was rated as having two domains at high risk of
bias); the primary outcome was originally specified as incidence
of AOM, but was reported as proportion of children with AOM
(due to variation in time points at which studies reported the
outcome); and several outcomes had to be omitted, whilst others
were added to the Summary of findings for the main comparison
due to paucity or availability of evidence, respectively.
Agreements and disagreements with other
studies or reviews
A previous systematic review found some evidence (in 4 out of 14
RCTs) for efficacy of probiotics as prophylaxis against the symp-
toms, but not the incidence, of acute respiratory tract infections
in 3764 adults and children (Vouloumanou 2009). Nometa-anal-
ysis was undertaken due to perceived heterogeneity of the inter-
ventions, populations, and diseases. A more recent systematic re-
view and meta-analysis of 15 RCTs restricted to 5121 children
also found evidence for a preventive reduction in the duration of
acute respiratory tract infections (including AOM as a secondary
outcome) in three of the trials, by about 0.75 of a day per year
(Laursen 2018). (The authors were able to extract unpublished
AOM-specific data from their own RCT, which was one of the
trials included in the meta-analysis, Laursen 2017b).
It thus seems that our review is in accordance with this older
literature.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A range of different probiotics may provide protection against
acute otitismedia (AOM) in childrennot prone toAOM, although
it is possible that this effect is due to a bias not detected by our
methods (such as publication bias, to account for the unexpected
finding of better efficacy for non-otitis-prone children than otitis-
prone ones, notwithstanding several biologically plausible expla-
nations).
Many uncertainties remain about the use of probiotics to protect
children from AOM: not just the concern that this is not a real
effect (from bias distortion), but also about the nature of the in-
tervention (can standard preparations of the probiotic be sourced
for wholesale clinical practice), and a persistent concern that there
may be insufficient data about safety from long-term observational
trials (even though some trial data suggest they are safe in im-
munocompetent people) (Cohen 2018).
Uncertainties about the optimal strain, as well as the duration,
frequency, and timing of probiotics administration, hamper the
interpretation of results.
Implications for research
There is a clear need for more, and larger, well-conducted ran-
domised controlled trials to test readily available probiotic prepara-
tions for AOM. Those randomised controlled trials should evalu-
ate a variety of probiotic strains, as well as the duration, frequency,
and timing of probiotic administration, as the optimal regimen is
currently unclear. There is also either a paucity or an absence of
evidence on the impact of probiotics on severity of AOM, median
duration of AOM episodes, need for use of antibiotics, antimi-
crobial resistance, time off work for parent or carer, hearing loss,
referrals to specialists, and quality of life (using validated tools).
Uniform reporting of outcomes is crucial - for example reporting
of antibiotic use varied significantly (e.g. as number of antibiotic
courses, per cent of participants taking antibiotics, mean number
of antibiotics prescriptions, days with antibiotic treatment, etc.),
limiting its interpretive value. Finally, identifying children most
likely to benefit fromprobiotics is an important research goal. This
might include determining whether probiotics administered from
shortly after birth protect high-risk (e.g. Indigenous) infants from
AOM during the first years of life.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cohen 2013a
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: centralised randomisation without stratification was used
with the Trial Balance programme on an Internet-based server to assign participants to
groups
Blinding: double-blind
Duration: 12 months
Exclusions postrandomisation: 236 randomised, 12 declined postrandomisation, 224
enrolled
Losses to follow-up:
Stage 1: probiotic group: 11 dropouts due to non-compliance with overall follow-up;
control group: 11 dropouts due to non-compliance with overall follow-up
Subsequently: probiotic group: 18 (8 due to non-compliance with treatment, 4 for
personal reasons, 1 adenoidectomy scheduled, 1 adenoidectomy, 2 unknown, 5 adverse
events); control group: 18 (9 non-compliance with treatment, 6 personal reasons, 1
adenoidectomy, 1 ichthyosis, 1 unknown, 1 tympanostomy)
Participants Country: France
Setting: children were enrolled by paediatricians
Number of participants: 236 randomised (224 enrolled): 112 probiotic/prebiotic group,
112 control
Age (mean +/- SD): 10.2 +/- 1.7 months
Inclusion criteria: healthy infants, 7 to 13 months old, full-term birth, weight ≥ 6 kg at
enrolment, AOM at the pre-inclusion visit treated with an antibiotic based on French
guidelines and able to tolerate oral formula of 300 mL per day, at high risk of AOM
(exposed to other children via day-care centre attendance or with ≥ 2 siblings), history
of at least 1 episode of AOM before the current one
Exclusion criteria: twins, children with underlying chronic disease, allergy to cow’s milk
protein, or participating in another clinical study
Interventions Treatment group: NAN 3 formula with probiotic (Streptococcus thermophilus nCC 2496,
Streptococcus salivarius dSM 13084, Lactobacillus rhamnosus lPr CgMCC 1.3724) and
preB (raftilose/raftiline). Dose: S thermophilus: 1 × 107 CFU/g, S salivarius: 2.5 × 107
CFU/g, L rhamnosus: 1 × 107 CFU/g; aiming for 300 to 630 mL of formula consumed
per day, for 12 months
Comparator group: NAN 3 formula alone (placebo); aiming for 300 to 630 mL con-
sumed per day, for 12 months
Outcomes Primary outcome(s): incidence of AOM in each group in the 12 months
Secondary outcome(s):URTI incidence, LRTI incidence, number of antibiotic treatment
courses, number of children without a new episode of AOM, number of children with
recurring AOM (3 episodes in 6 months or 4 episodes in 12 months)
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Cohen 2013a (Continued)
Notes Authors’ COIs: 1 of the authors employed by study funder
Funding: financial support provided by Nestle. Role of the funder in design, collection,
analysis, interpretation of data, the writing of the manuscript, decision to submit the
manuscript was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised randomisationwithout stratifi-
cation was used with the Trial Balance pro-
gramme to assign participants to groups
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as “double blind”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons provided.
Selective reporting (reporting bias) Unclear risk All outcomes reported except incidence of
URTIs (a secondary outcome)
Other bias High risk 1 of the authors employed by study funder.
Financial support provided by Nestle. Role
of the funder in design, collection, anal-
ysis, interpretation of data, the writing of
the manuscript, decision to submit the
manuscript not reported
Other authors state no conflicts of interest
or other funding to disclose
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Corsello 2017
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: randomisation was based on a list with consecutive numbers
with an allocation ratio of 1:1 between groups
Blinding: double-blind
Duration: 90 days
Exclusions postrandomisation: no child refused to participate after randomisation, and
all of the children received the allocated intervention
Losses to follow-up: probiotic 7 (reasons NR); placebo 13 (reasons NR)
Participants Country: Italy
Setting: children in the Italian public health system; recruited by paediatricians
Number of participants: 146 randomised: 73 treatment group; 73 comparator group
Age (mean +/- SD): 33 +/- 9 months
Inclusion criteria: healthy children aged 12 to 48 months who were attending day care
or preschool at least 5 days a week and who were regularly checked by the paediatricians
involved in the trial were considered for the study, and were consecutively contacted
during scheduled medical examinations at the paediatrician’s office
Exclusion criteria: age < 12 months or > 48 months, concomitant chronic infections,
chronic systemic diseases, chronic inflammatory bowel diseases, autoimmune diseases,
immunodeficiency, malignancy, metabolic diseases, chronic respiratory tract diseases
including respiratory allergies and cystic fibrosis, malformations of gastrointestinal or
urinary or respiratory tract, history of respiratory or gastrointestinal or urinary tract
surgery, congenital cardiac defects, functional bowel disorders, suspected or challenge-
proven food allergy, food intolerances, severemalnutrition (Z-score for weight-for-height
< 3 SD scores), and use of antibiotics or pre/pro/synbiotics or immune-stimulating
products in the 2 weeks before study enrolment. Siblings of participants enrolled in the
study were not allowed to participate in the trial
Interventions Treatment group: 7 g cow’s skim milk fermented with Lactobacillus paracasei (CBA L74)
, daily, for 90 days
Comparator group: placebo (maltodextrins, with an energy content similar to that of
the fermented milk), daily, for 90 days
Outcomes Primary outcome(s): the rate of children experiencing at least 1 episode of common
infectious disease
Secondary outcome(s): total number of common infectious diseases, use of medications
(antibiotics, antipyretics, corticosteroids), emergency departmentmedical examinations,
hospitalisations, days of work lost by the parents, days of school lost by the children,
faecal levels of α- and β-defensins, cathelicidin (LL-37), and secretory immunoglobulin
A (sIgA), adverse events
Notes Authors’ COIs: the authors declare they have no conflict of interest
Funding: unrestricted grant from Heinz Italia (affiliate of Kraft Heinz Company). The
funder had no influence on design, collection, analysis, interpretation of data, the writing
of the manuscript, or the decision to submit the manuscript
The trialled probiotic was manufactured by Heinz Italia SpA.
Note regarding meta-analysis: the study reports separate numbers for rhinitis, pharyn-
gitis, laryngitis, tracheitis, otitis, for “common infectious diseases observed during the
study period”. For the ’difference in other infections’ (ARIs) outcome, we reported the
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numbers for rhinitis only so as not to double count participants; when the numbers of
all ARIs (rhinitis, pharyngitis, laryngitis, tracheitis, AOM) were added, they exceeded
the number of children in the group, suggesting that at least some of the children had
more than 1 ARI during the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The study is described as randomised; base-
line characteristics appear similar (Table 2)
Allocation concealment (selection bias) Unclear risk Not clearly reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The investigators were blinded to the treat-
ment at all times. Intervention and control
were in similar packaging, and products ap-
peared the same
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A biostatistician blinded to the treatment
allocation performed the statistical analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition was reported for both arms, but
no reasons provided. As attrition was less
than 20% in both arms, we judged the risk
of bias to be low
Selective reporting (reporting bias) Unclear risk Emergency department visits (secondary
outcome) not reported
Other bias Low risk Authors’ COIs: the authors declare they
have no conflict of interest
Funding: unrestricted grant from Heinz
Italia (affiliate of Kraft Heinz Company)
. The funder had no influence on design,
collection, analysis, interpretation of data,
the writing of the manuscript, decision to
submit the manuscript
The trialled probiotic wasmanufactured by
Heinz Italia SpA.
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Di Nardo 2014
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: allocation schedule was computer generated, using a random
permuted blocks algorithm
Blinding: double-blinded
Duration: 6 months
Exclusions postrandomisation: none
Losses to follow-up: 1 discontinued in placebo group (consent withdrawn)
Participants Country: Italy
Setting: Dept of Paediatrics, University of Rome “La Sapienza”
Number of participants: 61 randomised; 30 probiotic, 31 placebo
Age (mean +/- SD): NR. Median: 17.5 years; range: 6 to 29 years
Inclusion criteria: patients with cystic fibrosis, FEV1 > 70%; no inhaled or systemic
corticosteroids; no anti-inflammatory drugs, antileukotrienes, and mast cell membrane
stabilisers; and no serious organ involvement. (Although this study technically meets the
exclusion criteria as it involves patients with cystic fibrosis, we have included this study
because the study only included those with mild disease, who had limited respiratory
impairment, and had not had a recent change in treatment.)
Exclusion criteria: history of pulmonary exacerbationor upper respiratory infection in the
previous 2 months; changes in medications in the last 2 months; history of haemoptysis
in the last 2 months; and colonisation with Burkholderia cepacia or mycobacteria
Interventions Treatment group: probiotic Lactobacillus reuteri ATCC55730; 5 drops per day (1010
CFU) for 6 months
Comparator group: the placebo was packed in identical bottles, had the same colour,
weight, smell, and taste of the probiotic formulation; 5 drops per day for 6 months
Outcomes Primary outcome(s): number of episodes of pulmonary exacerbations; number and du-
ration of hospital admissions made for pulmonary exacerbations; number of GI and
upper respiratory tract infections
Secondary outcome(s): change in qualitative and quantitative bacteria present in the
sputum; FEV1; change in faecal calprotectin concentration; IL-8 and TNF-a levels in
plasma and induced sputum
Notes Authors’ COIs: the authors report that they have no conflicts of interest
Funding: intervention andplacebo supplied by Italchimici (Pomezia, Italy), which hadno
role in the conception, design, conduct of the study, or in the analysis and interpretation
of the data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised; no significant differences
in baseline characteristics between the 2
groups
Allocation concealment (selection bias) Low risk Allocation schedule computer generated
and fully concealed from doctors
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as double-blind; doctors
and participants blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome measures of efficacy were
recorded by investigators completely un-
aware of group assignment; unblinding
procedures were performed after the study
was completed and the statistical analysis
carried out
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Intervention and placebo supplied by
Italchimici (Pomezia, Italy), who had no
role in the conception, design, conduct of
the study, or in the analysis and interpreta-
tion of the data
The authors reported that they had no con-
flicts of interest.
Di Pierro 2016
Methods Study design: 2-arm, controlled, randomised clinical study
Method of randomisation: individuals were randomised into groups by toss of a coin
Blinding: unblinded
Duration: 180 days
Exclusions postrandomisation: NR
Losses to follow-up: the authors state that “none of the children were withdrawn from
the study”
Participants Country: Italy
Setting: unclear
Number of participants: 222 randomised; 111 treatment group, 111 placebo
Age (mean +/- SD): treated group males: 36 +/- 3.2 months, females: 34 +/- 3 months;
untreated group males: 35 +/- 3 months, females: 35 +/- 3.6 months
Inclusion criteria: children around 3 years of age and soon to attend the first year of
kindergarten; free of streptococcal disease, as established by a rapid throat swab test for
group A streptococcus; none were clinically ill on enrolment
Exclusion criteria: immunocompromised children; had undergone tonsillectomy or had
an indication for adeno-tonsillectomy; had a history of rheumatic disorders, bron-
chospasm, and/or a diagnosis of asthma and/or allergy; a diagnosed respiratory or sig-
nificant systemic disorder; were either undergoing current pharmacological therapies to
prevent recurrent respiratory infections or presented with conditions that could favour
the development of AOM, including severe atopy, acquired or congenital immunode-
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ficiency, cleft palate, a chronically ruptured eardrum, craniofacial abnormalities or ob-
structive adenoids, sleep apnoea syndrome, or placement of tympanostomy tubes
Interventions Treatment group: Streptococcus salivarious K12 (i.e. BLIS K12) probiotic strain, formu-
lated as slowly dissolving oral tablets; containing no less than 1 billion CFU/tablet of S
salivarious K12, 1 tablet/day, dissolved slowly in the mouth after brushing teeth/imme-
diately before going to sleep, for 180 consecutive days
Comparator group: untreated
Outcomes Primary/secondary outcome(s): not specified, but the study states that it aimed to evaluate
the following: (1) the onset of side effects or symptoms of toxicity while the product
was being administered; (2) the efficacy of BLIS K12 in the prevention of Streptococcus
pyogenes infections (pharyngo-tonsillitis and scarlet fever) during 6 months of treatment
and a 3-month follow-up period; (3) the efficacy of BLIS K12 in reducing the occurrence
of AOM
Notes Authors’ COIs: first author is the main formulator of the tested product and is involved
in the Scientific Council of the company (Omeopiacenza) trading the tested product.
The other authors report no conflicts of interest
Funding: NR
Note regarding meta-analysis: this study only reports “pharyngo-tonsillitis” rather than
ARIs generally (as other studies do in this analysis); we included these data in the analysis
of the ’difference in other infections’ outcome
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomised by tossed coin”; Table 1 sug-
gests randomisation worked
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Untreated group did not receive any
treatment (i.e. unlikely patients/doctors
blinded)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk “None of the children were withdrawn
from the study”
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Authors’ COIs: first author is the main for-
mulator of the tested product and is in-
volved in the ScientificCouncil of the com-
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pany (Omeopiacenza) trading the tested
product. The other authors report no con-
flicts of interest
Funding for the trial and the role of the
funder: NR
Hatakka 2001a
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: computer-generated, blocked randomisation list; block size
of 4, stratified according to age (< 3 years, and 3 years and over) and day-care centre (18
centres)
Blinding: double-blinded
Duration: 7 months
Exclusions postrandomisation: discontinued before intervention: probiotic 14, placebo
9
Losses to follow-up: probiotic 30 (9 moving away from the area, 2 sickness, 8 other
reasons, 11 unknown); placebo 28 (11 moving away from the area, 3 non-compliance,
3 sickness, 4 other reasons, 7 unknown)
Participants Country: Finland
Setting: day-care centres in Helsinki
Number of participants: randomised 594; probiotic 296, control 298
Age (mean, range): probiotic 4.6 (1.3 to 6.8) years, control 4.4 (1.3 to 6.7) years
Inclusion criteria: healthy children aged1 to6 years, attendingmunicipal day-care centres
Exclusion criteria: children with allergy to cow’s milk, lactose intolerance, severe food
allergy, and other severe chronic diseases
Interventions Treatment group: Lactobacillus milk (Gefilus, Valio, Riihimäki, Finland) containing 1%
fat and 5 to 10 x 105 CFU/mL of strain Lactobacillus rhamnosus GG (ATCC 53103); 3
times a day, 5 days a week, for 7 months over the course of the winter
Comparator group: control milk had the same composition asLactobacillusmilk, but did
not contain Lactobacillus; 3 times a day, 5 days a week, for 7 months over the course of
the winter
Outcomes Primary outcome(s): the number of days with respiratory and gastrointestinal symptoms
or days with any illness; absences from day-care centre because of illness; number of chil-
dren with URTIs with complications (AOM and sinusitis) and LRTIs (acute bronchitis
and pneumonia) as diagnosed by a doctor; antibiotic treatments during the 7-month
intervention
Secondary outcome(s): correlation between the amount of milk consumed and the num-
ber of days with symptoms; symptom score (measuring the overall burden of symptoms)
Notes Authors’ COIs: KH (first author) has been employed by Valio Research Centre (man-
ufacturer of the trialled probiotic) for 2 of the past 5 years. MS and RK are employed
by Valio Research Centre. ES has given 2 educational presentations on Lactobacillus GG
for Valio, and TP has received consulting fees from Valio
Funding: Valio Research and Development, Helsinki, Finland. The University of
Helsinki and the City of Helsinki participated in the funding by providing supervision
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and technical help. Role of the funders in design, collection, analysis, interpretation of
data, the writing of the manuscript, decision to submit the manuscript not reported
Note regarding meta-analysis: for the ’difference in other infections (ARI)’ outcome, we
used data reporting “all infections together” (context suggests these were only respiratory
infections) having first subtracted the number of children with AOM from this number
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated using a computer-gen-
erated randomisation list
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Day-care staff, parents, children, and inves-
tigators were unaware of which milk carton
contained Lactobacillus until the intention-
to-treat analysis was performed.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear whether outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported in both arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Authors’ COIs: KH (first author) has been
employed by Valio Research Centre (man-
ufacturer of the trialled probiotic) for 2 of
the past 5 years. MS and RK are employed
by Valio Research Centre. ES has given 2
educational presentations on Lactobacillus
GG for Valio, and TP has received consult-
ing fees from Valio
Funding: Valio Research and Develop-
ment, Helsinki, Finland. The University of
Helsinki and the City of Helsinki partici-
pated in the funding by providing supervi-
sion and technical help. Role of the funders
in design, collection, analysis, interpreta-
tion of data, the writing of the manuscript,
decision to submit the manuscript not re-
ported
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Hatakka 2007a
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: computer-generated blocked randomisation list drawn up by
a statistician; block size of 4, stratified by gender, age (< 3 years old, ≥ 3 years old), and
care type (home or small-group care or day care)
Blinding: double-blinded
Duration: 6 months
Exclusions postrandomisation: none
Losses to follow-up: probiotic 20 (4 sickness, 5 non-compliance, 5 personal reasons,
5 unknown, 1 adverse events); placebo 20 (3 sickness, 8 non-compliance, 0 personal
reasons, 7 unknown, 2 tympanostomy)
Participants Country: Finland
Setting: NR
Number of participants: 309 randomised; probiotic 155, placebo 154
Age (mean, range): probiotic group: 2.4 (0.8 to 6.0) years, placebo: 2.4 (0.9 to 5.6) years
Inclusion criteria: at least 4 episodes of AOM during the preceding 12 months, or at
least 3 episodes during the preceding 6 months
Exclusion criteria: children on regular medication, with chronic illnesses, Down’s syn-
drome, lip or palatal cleft, otitis media with effusion, or who were scheduled for tympa-
nostomy or adenoidectomy during the study were excluded; those who had undergone
tympanostomy or adenoidectomy during the preceding 6 months were also excluded
unless they had suffered at least 3 episodes of AOM since the operations
Interventions Treatment group: gelatin capsule containing a combination of probiotic bacteria (Lac-
tobacillus rhamnosusGG, ATCC 53103; L rhamnosus LC 705; Bifidobacterium breve 99;
Propionibacterium freudenreichii subsp. shermanii) 8 to 9 x 109 CFU/capsule of each
strain, 1 capsule daily for 6 months
Comparator group: capsule containing cellulose microcrystalline (identical looking to
active intervention), 1 capsule daily for 6 months
Outcomes Primary outcome(s): occurrence and duration of AOM episodes
Secondary outcome(s): frequency of pathogen carriage, the occurrence of recurrent UR-
TIs, and the number of antimicrobial treatments
Notes Authors’ COIs: several authors employed or remunerated by manufacturer of the trialled
probiotic
Funding: manufacturer of trialled probiotic (Valio Ltd) andHelsinki University Hospital
Research Fund funded the study. Role of the funders in design, collection, analysis,
interpretation of data, the writing of the manuscript, decision to submit the manuscript
not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated blocked randomisa-
tion list drawn by the statistician
Allocation concealment (selection bias) Unclear risk NR
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Investigators, parents, and children were all
unaware of which treatment group each
child was in until the statistical analysis
was performed; capsules were delivered in
coded containers
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, reasons
provided.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Authors’ COIs: several authors employed
or remunerated by manufacturer of the tri-
alled probiotic
Funding: manufacturer of trialled probi-
otic (Valio Ltd) and Helsinki University
Hospital Research Fund funded the study.
Role of the funders in design, collection,
analysis, interpretation of data, the writing
of the manuscript, decision to submit the
manuscript not reported
Hojsak 2010a
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: randomisation performedwith computer-generated numbers
Blinding: double-blinded
Duration: 3 months
Exclusions postrandomisation: none
Losses to follow-up: probiotic 12 (8 did not want to drink product anymore, 4 did not
like the taste of product); placebo 15 (9 did not want to drink product anymore, 6 did
not like the taste of product)
Participants Country: Croatia
Setting: day-care centres in Zagreb
Number of participants: 281 randomised; 139 probiotic, 142 placebo
Age (mean, range): probiotic 51.9 (13 to 86) months; placebo 53.6 (13 to 83) months
Inclusion criteria: children whose parents or legal guardians provided written informed
consent and who did not meet any of the exclusion criteria
Exclusion criteria: children with cow’s milk allergy (probiotics were given in a fermented
cow’s milk product); those who were receiving probiotic or prebiotic products, or both
prior to or at the time of enrolment; those who had a neoplasm, other chronic severe
illness, or immunodeficiency; and children who disliked fermented milk products
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Interventions Treatment group: Lactobacillus rhamnosus strain GG (LGG strain from Valio) admin-
istered in 100 mL of a fermented milk product at a dose of 1 x 109 CFU, once daily
during the 3-month intervention period (19 November 2007 to 20 February 2008)
Comparator group: placebo was the same postpasteurised fermented milk product (100
mL) without LGG, once daily during the 3-month intervention period (19 November
2007 to 20 February 2008)
Outcomes Primary outcome(s): (1) number of children with GI infections; (2) number of children
with respiratory tract infections confirmed by physician
Secondary outcome(s): (1) number of children with vomiting episodes; (2) number of
children with diarrhoeal episodes; (3) number of GI infections lasting longer than 2 days;
(4) number of children with URTI, including rhinitis, pharyngitis, sinusitis, otitis, and
the common cold; (5) number of children with LRTIs, including pneumonia, bronchitis,
and bronchiolitis; (6) number of respiratory tract infections lasting longer than 3 days;
(7) total number of days with respiratory and GI symptoms; and (8) number of days
absent from day-care centre due to infections
Notes Authors’ COIs: the authors report that before, during, or after the study, none of the
authors received any funds for their work, which was exclusively voluntary, and the
authors state that they have no conflict of interest
Funding: probiotic and placebo supplied by Dukat Dairy Industry (dairy company in
Croatia), who had no role in the conception, design, or conduct of the study or in the
analysis or interpretation of the data
Note regarding meta-analysis: this study reports the number of children with LRTIs
and the number of children with URTIs separately. To report this outcome in the analysis
of difference in other infections, we added the number of children with LRTI and URTI
and subtracted from this number the number of children with AOM
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation procedure performed with
computer-generated numbers
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as double-blind; neither
research staff nor childrenwere aware of the
real nature of the product. Probiotic and
placebo were packed in identical bottles,
and were of the same colour, weight, smell,
and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unblinding procedure was performed after
the study was completed and after the sta-
tistical analyses were finalised
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Authors’ COIs: the authors report that be-
fore, during, or after the study, none of the
authors received any funds for their work,
which was exclusively voluntary, and the
authors state that they have no conflict of
interest
Funding: probiotic and placebo supplied
by Dukat Dairy Industry (dairy company
in Croatia), who had no role in the concep-
tion, design, or conduct of the study or in
the analysis or interpretation of the data
Hojsak 2016
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: used Random Allocation Software, in which every patient
got a number and received the preparation successively; randomisation in blocks of 6
Blinding: double-blinded
Duration: 90 days
Exclusions postrandomisation: none
Losses to follow-up: probiotic 5 (5 discontinued product use); placebo 7 (7 discontinued
product use)
Participants Country: Croatia
Setting: day cares in Zagreb, Croatia
Number of participants: 210 randomised; 104 probiotic, 106 placebo
Age (mean, range): probiotic 4.49 (1.43 to 7.48) years; placebo 4.44 (1.44 to 6.79) years
Inclusion criteria: children who attended day-care centres in 3 separate locations in the
Zagreb area were eligible for the study, whose parents or legal guardians signed written
informed consent, and who did not meet any of the exclusion criteria were included into
the study
Exclusion criteria: children receiving probiotic or prebiotic products, or both 2 weeks
prior to or at the time of enrolment; those who had any severe chronic illness, including
neoplasm and immunodeficiency
Interventions Treatment group: a sachet containing 1 g of powder (maltodextrin with BB-12 at a dose
of 109 CFU; the powder was mixed in about 20 mL of milk, water, cordial, or drinking
yogurt or spread on a spoon of yogurt and consumed immediately thereafter, at home
in the evening together with a meal. Once daily for 90 days (starting 23 January 2013)
Comparator group: a sachet containing 1 g of powder (maltodextrin); the powder was
mixed in about 20 mL of milk, water, cordial, or drinking yogurt or spread on a spoon
of yogurt and consumed immediately thereafter, at home in the evening together with a
meal. Once daily for 90 days (starting 23 January 2013)
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Outcomes Primary outcome(s): number of children with common GI and respiratory infections.
GI infections included diarrhoea, vomiting, both; ARIs included pharyngitis, otitis,
common cold, pneumonia, bronchitis, and bronchiolitis diagnosed by physician
Secondary outcome(s): duration of symptoms of common infections (GI and ARIs);
number of children with GI infections; number of children with ARIs; absence from
day-care centre due to infections; use of antibiotics
Notes Authors’ COIs: the article states “none declared”
Funding: Chr.Hansen, Denmark (manufacturer of the probiotic). The role of the funder
in the conception, design, or conduct of the study or in the analysis or interpretation of
the data was not reported
Note regarding meta-analysis: for the ’difference in other infections’ outcome, we have
reported the numbers of children with ARIs but subtracted from those the number of
children with AOM so as not to double count
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using Random Allocation
Software
Allocation concealment (selection bias) Low risk “To ensure allocation concealment, an in-
dependent person prepared the randomisa-
tion schedule.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study personnel, parents, and guardians
were unaware of the group assignments.
Products were of the same taste, colour, and
smell, and were packed in identical sachets.
The real nature of the product was not re-
vealed to research staff and participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Statistical plan and complete statistical
analysis was performed prior to unblind-
ing, and all analyses were performed ac-
cording to a written statistical analysis plan
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Authors’ COIs: the article states “none de-
clared”
Funding: Chr. Hansen, Denmark (manu-
facturer of the probiotic). The role of the
funder in the conception, design, or con-
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duct of the study or in the analysis or in-
terpretation of the data was not reported
Karpova 2015
Methods Study design: 2-arm, controlled, randomised clinical study
Method of randomisation: the article states that it used “simple randomisation” (further
details NR)
Blinding: none (open)
Duration: 30 days
Exclusions postrandomisation: probiotics 15 (3 allergic reaction, 12 reasons not pro-
vided); control 19 (reasons not provided). 3 participants with allergic reaction were trans-
ferred to the control group and analysed as part of the control group
Losses to follow-up: none
Participants Country: Russia
Setting: children attending organised children’s groups
Number of participants: 250 children; 128 probiotic, 122 control; the study reports on
113 probiotic, 106 control
Age: mean NR. Median NR. Range: 6 to 7 years old
Inclusion criteria: children attending organised children’s groups, aged 6 to 7 years, who
had clinical signs of chronic adenoiditis
Exclusion criteria: intolerance to flavouring components that make up the probiotic
complex; presence of concomitant diseases that change the natural course of the disease,
affect the result of therapy, and/or disrupt the possibility of subjective assessment of the
symptoms of the disease (psychoneurological pathology, diabetesmellitus, blood diseases,
oncological diseases, immunodeficiency conditions, gastrointestinal tract diseases, etc.)
Interventions Treatment group: Streptococccus salivarius K12-based probiotic complex in combination
with the nasal-douche, once daily at night for 30 days
Comparator group: nasal-douche alone, once daily at night for 30 days
Outcomes Primary/secondary outcome(s): unclear. The following outcomes listed: frequency of
diagnosed adenoiditis, the need for topical anti-inflammatory therapy, complications of
adenoiditis (AOM and acute rhinosinusitis), the need for systemic antibacterial drugs,
side effects
Notes Authors’ COIs: NR
Funding: NR. The role of the funder (if any) in the conception, design, or conduct of
the study or in the analysis or interpretation of the data was not reported
Note regarding meta-analysis: for the analysis of difference in the use of antibiotics, we
used the numbers reported in this study of children “prescribed antibiotics for AOM and
acute rhinitis” (the numbers are reported collectively rather than individually by disease)
in the ’use of antibiotics for AOM’ subgroup rather than the ’use of antibiotics for any
infection’ subgroup as the former is a closer match
For the analysis of difference in other infections, we have reported the numbers for
children with acute rhinosinusitis, as those are the only reported numbers (unlike other
studies, which report ’ARIs’ more collectively)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study states that it is randomised, but
method not reported; no baseline charac-
teristics provided to assess the result of ran-
domisation
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk NR
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Unclear risk Side effects are listed as one of the out-
comes, but not reported
Other bias High risk Authors’ COIs: NR
Funding: NR. The role of the funder (if
any) in the conception, design, or conduct
of the study or in the analysis or interpre-
tation of the data was not reported
Maldonado 2012
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: computer-generated randomisation list
Blinding: double-blinded
Duration: 6 months
Exclusions postrandomisation: probiotic 0; placebo 7 (7 did not receive the formula due
to mistake in sending)
Losses to follow-up: probiotic 7 (1moved out of study area, 4 discontinued intervention/
did not attend study visits, 2 excluded from analysis/incomplete data); placebo 13 (2
discontinued intervention, 6 discontinued intervention/did not attend study visits, 5
excluded from analysis/incomplete data)
Participants Country: Spain
Setting: paediatric departments of 3 hospitals
Number of participants: 215 randomised; probiotic 117, control 98
Age (mean +/- SD): probiotic 6.5 +/- 1.2 months; control 6.5 +/- 1.3 months
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Inclusion criteria: healthy 6-month-old infants who were exclusively formula fed; live in
proximity to the hospitals, child was delivered at the hospital and/or made regular visits
to the paediatrician
Exclusion criteria: GI disorders (history of chronic diarrhoea or constipation, gastro-
oesophageal reflux), GI surgery, cow’s milk protein allergy, metabolic disorders (diabetes,
lactose intolerance), immunodeficiency, antibiotic prescription 1 week before inclusion,
and previous use of formula containing prebiotics or probiotics
Interventions Treatment group: standard powdered formula with nutritional composition in accor-
dance with current European Union regulations, supplemented with (0.4 g/100 mL)
galactooligosaccharide plus Lactobacillus fermentum CECT5716 (L fermentum Hered-
itum, Biosearch Life, Granada, Spain) at an average dose of 2 x 108 CFU/day. The
amount of formula per day was paediatrician-prescribed; duration was 6 months
Comparator group: standard powdered formula with nutritional composition in accor-
dance with current EuropeanUnion regulations, supplemented with galactooligosaccha-
ride only (0.4 g/100 mL). The amount of formula per day was paediatrician-prescribed;
duration was 6 months
Outcomes Primary outcome(s): incidence of infections (including GI, ARI, AOM, urinary, and
other, less common infections)
Secondary outcome(s): evolution of weight, length, and head circumference, fever
episodes, antibiotic prescriptions, and concentrations of short-chain fatty acids (SCFAs)
, immunoglobulin (Ig) A, and microbiota composition in faeces; the incidence of recur-
rent (≥ 3 events) respiratory infections
Notes Authors’ COIs: the article states that “the authors report no conflict of interest” (NB:
corresponding author lists affiliation with Puleva Food SL, which manufactured the
formulas used in the trial)
Funding: Puleva Food SL (manufacturer of the formulas; provided the formulas)
The role of the funder (if any) in the conception, design, or conduct of the study or in
the analysis or interpretation of the data was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list
(SIGESMU, Madrid, Spain)
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as double blind; “to en-
sure blinding, both formulas submitted to
a sensorial test by an expert panel that finds
both products to be identical”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data were analysed with STATA by a
blinded statistician.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Authors’ COIs: the article states that “the
authors report no conflict of interest” (NB:
corresponding author lists affiliation with
Puleva Food SL, which manufactured the
formulas used in the trial)
Funding: Puleva Food SL (manufacturer of
the formulas; provided the formulas)
The role of the funder (if any) in the con-
ception, design, or conduct of the study or
in the analysis or interpretation of the data
was not reported
Maldonado 2015
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: computer-generated randomisation list
Blinding: double-blinded
Duration: this is a 3-year follow-up of Maldonado 2012 (see above)
Exclusions postrandomisation: 121 assessed for eligibility; 5 not located, 6 declined to
participate; 110 included
Losses to follow-up: probiotic 10 (did not attend medical visits); placebo 9 (did not
attend medical visits)
Participants Country: Spain
Setting: children who completed the initial trial (Maldonado 2012)
Number of participants: 110 included; probiotic 55, control 55
Age (mean +/- SD): probiotic: 3.02 +/- 0.1 years; control: 3.02 +/- 0.1 years
Inclusion criteria: infants who had completed the previous trial (Maldonado 2012)
Exclusion criteria: NR
Interventions Treatment group (Maldonado 2012): standard powdered formula with nutritional com-
position in accordance with current EuropeanUnion regulations, supplemented with (0.
4 g/100 mL) galactooligosaccharide plus Lactobacillus fermentumCECT5716 (L fermen-
tumHereditum, Biosearch Life, Granada, Spain) at an average dose of 2 x 108 CFU/day.
The amount of formula per day was paediatrician-prescribed; duration was 6 months
Comparator group (Maldonado 2012): standard powdered formula with nutritional
composition in accordance with current European Union regulations, supplemented
with galactooligosaccharide only (0.4 g/100 mL). The amount of formula per day was
paediatrician-prescribed; duration was 6 months
Outcomes Primary outcome(s): anthropometric values including weight, length, and head circum-
ference at 3 years of age
Secondary outcome(s): incidence of non-acquired diseases (allergies and metabolic dis-
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eases), hospitalisations and surgical procedures, incidence of infections measured during
the final year of the study
Notes Authors’ COIs: MG, JM, MVR, KF, and ELH acknowledge no conflict of interest of
personal interest/gain in any company/organisation, or having received any financial
support from any industry-related organisation in the preparation of this article. ADV, JF,
andMOwork for Biosearch, owner of the patent of Lactobacillus fermentumCECT5716.
FLV works for Lactalis Puleva. JML is the recipient of a fellowship from the Fundación
Universidad-Empresa (Universidad de Granada, Spain)
Funding: the study was funded by HiPP GmbH & Co Vertrieb KG, Pfaffenhofen
(Germany) and Lactalis Puleva, Granada (Spain). Study sponsors participated in the
study design and the writing of the report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised in the original study (
Maldonado 2012)
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Original study described as double-blind;
not clear if the 2-year follow-up was also
blind for participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Authors’ COIs: MG, JM, MVR, KF, and
ELH acknowledge no conflict of interest
of personal interest/gain in any company/
organisation, or having received any finan-
cial support from any industry-related or-
ganisation in the preparation of this arti-
cle. ADV, JF, and MO work for Biosearch,
owner of the patent of Lactobacillus fermen-
tum CECT5716. FLV works for Lactalis
Puleva. JML is the recipient of a fellowship
from the Fundación Universidad-Empresa
(Universidad de Granada, Spain)
Funding: the study was funded by HiPP
GmbH & Co Vertrieb KG, Pfaffenhofen
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(Germany) and Lactalis Puleva, Granada
(Spain). Study sponsors participated in the
study design and the writing of the report
Marchisio 2015
Methods Study design: 2-arm, placebo-controlled, randomised controlled trial
Method of randomisation: using a random number generator, in a 1:1 ratio
Blinding: double-blinded
Duration: 3 months
Exclusions postrandomisation: none
Losses to follow-up: probiotic 0; placebo 3 (refused to continue study after first treatment
period)
Participants Country: Italy
Setting: Paediatric Highly Intensive Care Unit, Dept of Pathophysiology & Transplan-
tation, University of Milan
Number of participants: 100 randomised; 50 probiotic, 50 placebo
Age (mean +/- SD): probiotic: 2.7 +/- 1.1 years; placebo: 3.1 +/- 1.2 years
Inclusion criteria: children aged 1 to 5 years with histories of recurrent AOM (defined
as at least 3 episodes in the preceding 6 months or at least 4 episodes in the preceding
12 months with the most recent episode within the previous 2 to 8 weeks) who were
regularly followed up by the outpatient section of the Paediatric Highly Intensive Care
Unit. The minimum number of episodes of AOM for inclusion in the otitis-prone
group had to be diagnosed by pneumatic otoscopy performed by a trained investigator
and documented by medical records, and at least 2 episodes had to be supported by
tympanometric findings. At the time of enrolment, the children had to be free of AOM
but could be experiencing otitis media with effusion
Exclusion criteria: all factors that could favour the development of AOM, including severe
atopy, acquired or congenital immunodeficiency, cleft palate, a chronically ruptured
eardrum, craniofacial abnormalities or obstructive adenoids, sleep apnoea syndrome, or
the placement of tympanostomy tubes
Interventions Treatment group: Streptococcus salivarius 24SMB preparation (suspension of S salivarius
24SMB consisting of a minimum of 100 × 109 CFU/mL in 5 mL of saline); delivered
with a nasal spray that provided 5 × 109 CFU to each nostril; twice per day, 5 days each
month for 3 consecutive months
Comparator group: the placebo was based on saline with a colour and taste that were
indistinguishable from the preparation containing S salivarius. The placebo was admin-
istered with the same nasal spray and provided the same saline dose; twice per day, 5
days each month for 3 consecutive months
Outcomes Primary/secondary outcome(s): not clearly identified. The article states: “Three types of
outcome were considered, i.e., the total number of AOM episodes and the numbers of
complicated and uncomplicated episodes.”
Notes Authors’ COIs: the author(s) declare that they have no competing interests
Funding: this study was supported by a grant obtained from DMG Italia S.r.l. The role
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of the funder (if any) in the conception, design, or conduct of the study or in the analysis
or interpretation of the data was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by “a random number gener-
ator”
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as double-blinded; paedi-
atricians were blinded to treatment assign-
ments. Both groups’ sprays were labelled
with randomisation codes
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Sprays’ randomisation codes were revealed
only to the staff of the datamonitoring cen-
tre
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Unclear risk Outcomes not clearly identified as pri-
mary or secondary. Lists 3 outcomes (AOM
episodes, complicated AOM episodes, un-
complicated episodes), all of which are re-
ported, but the number of children treated
with antibiotics is also reported in the re-
sults
Other bias High risk Authors’ COIs: the author(s) declare that
they have no competing interests
Funding: this study was supported by a
grant obtained from DMG Italia S.r.l. The
role of the funder (if any) in the conception,
design, or conduct of the study or in the
analysis or interpretation of the data was
not reported
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Methods Study design: 3-arm, placebo-controlled, randomised clinical study
Method of randomisation: computer-generated randomisation list
Blinding: double-blinded
Duration: 3 months
Exclusions postrandomisation: probiotic in milk: 3 refused to participate after randomi-
sation; probiotic in rice: 21 refused to participate after randomisation; placebo: 17 re-
fused to participate after randomisation
Losses to follow-up: probiotic in milk (4); probiotic in rice (5); placebo (5)
Participants Country: Italy
Setting: family paediatricians in the Italian Public Health System
Number of participants: randomised 432: probiotic in milk: 144; probiotic in rice 144;
placebo 144
Age (mean +/- SD): probiotic in milk: 32 +/- 30 months; probiotic in rice: 31 +/- 11
months; placebo: 34 +/- 9 months
Inclusion criteria: consecutive healthy children (12 to 48 months of age) attending day
care or preschool at least 5 days a week
Exclusion criteria: age≤ 12 months or≥ 48 months, concomitant chronic systemic dis-
eases, congenital cardiac defects, gastrointestinal or urinary or respiratory tract surgery, ac-
tive tuberculosis, autoimmune diseases, immunodeficiency, chronic inflammatory bowel
diseases, cystic fibrosis, metabolic diseases, history of suspected or challenge-proved food
allergy, lactose intolerance, malignancy, chronic pulmonary diseases, malformations of
gastrointestinal or urinary or respiratory tract, severe malnutrition (Z score for weight-
for-height < 3 SD scores); use of pre/pro/synbiotics, antibiotics, or immune-stimulating
products in the 2 weeks before study enrolment
Interventions Probiotic in milk: cow’s milk fermented with Lactobacillus paracaseiCBA L74. 7 g/day of
study product diluted in maximum 150 mL of cow’s milk or water. Daily for 3 months
during the winter season
Probiotic in rice: rice fermented with L paracasei CBA L74. 7 g/day of study product
diluted in maximum 150 mL of cow’s milk or water. Daily for 3 months during the
winter season
Comparator group: placebo consisting of maltodextrins with similar energy content of
fermented milk and rice products. 7 g/day of study product diluted in maximum 150
mL of cow’s milk or water. Daily for 3 months during the winter season
Outcomes Primary outcome(s): the proportion of children experiencing at least 1 episode of com-
mon infectious disease
Secondary outcome(s): proportion of children with recurrent common infectious dis-
eases (i.e. 3 episodes), total number of common infectious diseases, use of medications
(antipyretics, antibiotics, or corticosteroids), emergency department visits, paediatric
visits, hospitalisations
Notes Authors’ COIs: the authors state that they have no financial relationships relevant to this
article to disclose. The authors have no conflicts of interest that are directly relevant to
the content of this paper
Funding: this work was supported in part by the Italian Ministry of Health Grant PE-
2011-02348447, and by an unrestricted grant from Heinz Italia SpA, Latina, Italy, an
affiliate of H.J. Heinz Company, Pittsburgh, PA, USA, devoted to the Department of
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TranslationalMedical Science of theUniversity ofNaples “Federico II”.However, neither
the Italian Ministry of Health nor Heinz Italia SpA, Latina, Italy, an affiliate of H.J.
Heinz Company, Pittsburgh, PA, USA had any influence on: 1) the study design, 2) the
collection, analysis, and interpretation of data; 3) the writing of the manuscript; and 4)
the decision to submit the manuscript for publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised according to a computer-gen-
erated randomisation list
Allocation concealment (selection bias) Low risk The paediatricians assigned each child to
the next available number on entry into the
trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Investigators were blinded to the treatment
at all times. Paediatricians, parents, and
childrenwere not aware of the dietary treat-
ment assigned
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Statistical analysis was blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for all 3 arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk Authors’ COIs: the authors state that they
have no financial relationships relevant to
this article to disclose. The authors have no
conflicts of interest that are directly relevant
to the content of this paper
Funding: this work was supported in part
by the ItalianMinistry of HealthGrant PE-
2011-02348447, and by an unrestricted
grant from Heinz Italia SpA, Latina, Italy,
an affiliate of H.J. Heinz Company, Pitts-
burgh, PA, USA, devoted to the Depart-
ment of Translational Medical Science of
the University of Naples “Federico II”.
However, neither the Italian Ministry of
Health nor Heinz Italia SpA, Latina, Italy,
an affiliate of H.J. Heinz Company, Pitts-
burgh, PA, USA had any influence on: 1)
the study design, 2) the collection, analysis,
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and interpretation of data; 3) the writing
of the manuscript; and 4) the decision to
submit the manuscript for publication
Rautava 2009
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: block randomisation with individual codes
Blinding: double-blinded
Duration: 10 to 12 months (infants < 2 months old were recruited and followed until
they were 12 months old)
Exclusions postrandomisation: none
Losses to follow-up: probiotic 2; placebo 1
Non-adherence to protocol: probiotic 9 (4 discontinued, 2 GI complaints, 2 inconve-
nience of powdered formula, 1 arduousness of study); placebo 4 (2 discontinued, 1 GI
complaints, 1 arduousness of study)
Participants Country: Finland
Setting: NR
Number of participants: 81 randomised; probiotics 38, placebo 43
Age (mean age in days at start of intervention): probiotics 38 (6 to 65), placebo 35 (2 to
59)
Inclusion criteria: need for infant formula before the age of 2 months
Exclusion criteria: infants with chronic disease
Interventions Treatment group: 1 x 1010 CFU of both Lactobacillus rhamnosus (Lactobacillus GG,
American type culture collection 53103; Valio Ltd, Helsinki, Finland) and Bifidobac-
terium lactis Bb-12 (Chr. Hansen A/S, Hoersholm, Denmark) in capsule, the contents
of which were supplemented to infant formula given at 1 feeding. Once daily, until the
age of 12 months
Comparator group: placebo capsule (microcrystalline cellulose) in capsule, the contents
of which were supplemented to infant formula given at 1 feeding. Once daily, until the
age of 12 months
Outcomes Primary outcome(s): incidence of early ARIs, doctor-diagnosed AOM, GIs occurring
before the age of 7 months
Secondary outcome(s): incidence of recurrent (3+) respective infections during the first
year of life
Notes Authors’ COIs: NR
Funding: Lactobacillus GG was acquired without cost from Valio Ltd, and Chr. Hansen
A/S providedB lactisBb-12 andmanufactured the probiotic andplacebo capsuleswithout
cost. The infant formula was provided without cost by Mead Johnson Nutrition. The
study was funded by the Microbes and Man research programme, the Academy of
Finland, and the Bristol-Myer Squibb Mead Johnson Foundation Unrestricted Research
Grant. The funding sources had no involvement in study design, collection, analysis,
and interpretation of data, writing of the report, or the decision to submit the paper for
publication
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by block randomisation with
individual codes
Allocation concealment (selection bias) Unclear risk The random allocation was generated in-
dependently from the investigators by the
manufacturer of the capsules (Chr. Hansen
A/S)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was double-blind; the code was
opened after all the infants had completed
the study and data had been edited
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear who performed the assessment or
whether or not they were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk LactobacillusGGwas acquiredwithout cost
from Valio Ltd, and Chr. Hansen A/S pro-
vided B lactis Bb-12 and manufactured
the probiotic and placebo capsules with-
out cost. The infant formula was provided
without cost by Mead Johnson Nutrition.
The study was funded by theMicrobes and
Man research programme, the Academy
of Finland, and the Bristol-Myer Squibb
Mead Johnson Foundation Unrestricted
Research Grant. The funding sources had
no involvement in study design, collection,
analysis, and interpretation of data, writing
of the report, or the decision to submit the
paper for publication. Author COIs not re-
ported
54Probiotics for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roos 2001a
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: randomisation was undertaken by a technician with no access
to information on the participants or doctors; no further details provided
Blinding: double-blinded
Duration: 3 months
Exclusions postrandomisation: not clear, of 132 children included, 108 (82%) were
eligible for analysis of efficacy (53 in the probiotic group and 55 in the placebo group)
and 126 (95%) for analysis of adverse events
Losses to follow-up: not reported by assigned group; main reasons for not being eligible
for the efficacy analysis were withdrawal from the study or refusal to start spray treatment
(8 children), inadequate handling of spray (4), and antibiotic treatment being received
for reasons other than AOM (3). The other 5 participants were either lost to follow-up
(2), allergic to penicillin (1), or it was not possible to determine whether a recurrence
had occurred because they were treated by another doctor during the study (2)
Participants Country: Sweden
Setting: ENT specialists at Lundby Hospital
Number of participants: 130 randomised; 108 eligible for efficacy analysis (53 in probi-
otic group, 55 in placebo group)
Age (mean, range): 23 months (6 months to 6 years)
Inclusion criteria: had had recurrent AOM and who had been either referred by their
general practitioner or a paediatrician to the open care unit of the ear, nose, and throat
department at Lundby Hospital or were directly seeking medical advice for ear pain; had
had at least 2 episodes of AOM during the past 6 months or 5 episodes during the past
year; at the next occurrence of ear pain the children were examined, and those with a
red or pale, bulging, thickened tympanic membrane were included in the study
Exclusion criteria: penicillin allergy, serious underlying disease, immunological defi-
ciency, a valvular heart defect, major lesions in the mouth or nose, a grommet in the ear,
or chronic otitis media
Interventions Treatment group: streptococcal spray (2 strains of Streptococcus sanguis, 2 strains of Smitis,
1 strain of S oralis), freeze-dried in skim milk, reconstituted in 0.9% sodium chloride
immediately prior to use; corresponding to a suspension of 5 x 108 CFU/mL. Children
with no recurrences during the last month received phenoxymethylpenicillin (n = 22),
and those with a recurrence within 1month received amoxicillin-clavulanic acid (n = 86)
, both twice a day for 10 days. Streptococcal spray was then sprayed into the nose for 10
days (3 puffs into each nostril, twice daily). At day 60, the same spray was administered
for another 10 days (3 puffs into each nostril, twice daily)
Comparator group: placebo comprised of skim milk powder (with the same texture
and colour as the spray). Children with no recurrences during the last month received
phenoxymethylpenicillin (n = 22), and those with recurrence within 1 month received
amoxicillin-clavulanic acid (n = 86), both twice a day for 10 days. Placebo spray was then
sprayed into the nose for 10 days (3 puffs into each nostril, twice daily). At day 60, the
same spray was administered for another 10 days (3 puffs into each nostril, twice daily)
Outcomes Primary outcome(s): recurrence of AOMduring follow-up; normal tympanic membrane
at the last valid visit
Secondary outcome(s): unclear
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Notes Authors’ COIs: the authors of this study have been co-operating for over 15 years in
the study of recurrent infections in the upper respiratory tract, and the present study
is a continuation of earlier studies on bacterial interference done by the authors. The
Medical Products Agency in Uppsala approved the design and suggested minor changes
Funding: SwedishNational Board for Industrial and Technical Development; Teknikbro
Foundation; Samariten Foundation. The role of the funder (if any) in the conception,
design, or conduct of the study or in the analysis or interpretation of the data was not
reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by a techni-
cian with no access to information on par-
ticipants or doctors
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study described as “double blind”; placebo
powder was the same texture and colour as
the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons provided.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Authors’ COIs: the authors of this study
have been co-operating for over 15 years
in the study of recurrent infections in the
upper respiratory tract, and the present
study is a continuation of earlier studies on
bacterial interference done by the authors.
The Medical Products Agency in Uppsala
approved the design and suggested minor
changes
Funding: Swedish National Board for
Industrial and Technical Development;
Teknikbro Foundation; Samariten Foun-
dation. The role of the funder (if any) in
the conception, design, or conduct of the
study or in the analysis or interpretation of
the data was not reported
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Stecksen-Blicks 2009
Methods Study design: 2-arm, placebo-controlled, cluster-randomised clinical study
Method of randomisation: clusters (different day cares) were randomly allocated to the
intervention or control regimen by a staff member at the local dairy by coin toss
Blinding: double-blinded
Duration: 21 months
Exclusions postrandomisation: none
Losses to follow-up:
Before 12 months: probiotic 23 (22 children moved to school after 3 months, 1 child
changed unit); control 39 (36 children moved to school after 3 months; 3 milk intoler-
ance)
After 12 months but before 21 months: probiotic 26 (moved to school after 15 months)
; control 31 (moved to school after 15 months)
Participants Country: Sweden
Setting: day-care centres
Number of participants: randomised 27 units (n = 248); probiotic 16 units (n = 133),
control 11 units (n = 115)
Age (mean +/- SD at baseline): probiotic 42.9 +/- 16.5 months; control 42.4 +/- 13.8
months
Inclusion criteria: children 1 to 5 years old, from 14 day-care centres located in Nord-
maling and Hörnefors
Exclusion criteria: severe chronic diseases, milk intolerance, or with a fluoride concen-
tration in piped drinking water exceeding 0.5 mg/L were excluded
Interventions Treatment group: 150 mL medium-fat milk (1.5%) at lunch; the milk was prepared by
the day-care staff by adding 1 colour-coded capsule (10 mL) to each litre of milk. The
capsules were kept frozen and contained fluoride and probiotic bacteria in skim milk to
give a final concentration of 2.5mg/L fluoride and 107 CFU/mL Lactobacillus rhamnosus
LB21 in the intervention group. The milk was served only on weekdays and not during
weekends, holidays, or vacation periods; once daily for 21 months
Comparator group: children were served 150 mL medium-fat milk (1.5%) at lunch.
Before serving, the milk was prepared by the day-care staff by adding 1 colour-coded
capsule (10 mL) to each litre of milk. The capsules in the control group contained only
skimmed milk and were identical in appearance except in colour code. The intervention
milk was served only on weekdays and not during weekends, holidays, or vacation
periods; once daily for 21 months
Outcomes Primary outcome(s): caries increment
Secondary outcome(s): “measures of general health”
Notes Authors’ COIs: NR
Funding: the probiotic strain was provided by Essum AB, Umeå, Sweden. The fluoride
solution was prepared at the university biochemical laboratory, and the capsules were
produced at the local dairy (Norrmejerier, Umeå, Sweden). The study was supported
financially by the County Council of Västerbotten (TUA) and the Borrow Foundation,
UK. Norrmejerier Ekonomisk Förening, Umeå, Sweden supported the study by prepa-
ration and distribution of the milk. The role of the funder (if any) in the conception,
design, or conduct of the study or in the analysis or interpretation of the data was not
reported
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Stecksen-Blicks 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Day-care units were randomly allocated by
a staff member at the local dairy by means
of coin tossing
Allocation concealment (selection bias) Low risk The units were referred to as blue or yel-
low units in order to conceal their alloca-
tion. The code was kept by an independent
monitor and was not unveiled until all data
were computerised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither the researchers nor the clinicians,
personnel, or families at the day-care cen-
tres knewwhether the childrenhad received
control or intervention milk during the
course of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons provided.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk Authors’ COIs: NR
Funding: the probiotic strain was provided
by Essum AB, Umeå, Sweden. The fluo-
ride solution was prepared at the univer-
sity biochemical laboratory, and the cap-
sules were produced at the local dairy
(Norrmejerier, Umeå, Sweden). The study
was supported financially by the County
Council of Västerbotten (TUA) and the
Borrow Foundation, UK. Norrmejerier
Ekonomisk Förening, Umeå, Sweden sup-
ported the study by preparation and distri-
bution of the milk. The role of the funder
(if any) in the conception, design, or con-
duct of the study or in the analysis or in-
terpretation of the data was not reported
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Taipale 2011
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: computer-generated randomisation list; blocks of 3
Blinding: double-blinded
Duration: approximately 7 months (from age 1 to 2 months to 8 months)
Exclusions postrandomisation: none
Losses to follow-up: probiotic group: 17 did not receive tablet; control group: 17 did
not receive tablet
Non-adherence to protocol: probiotic group 4 (2GI complaints, 2 arduousness of study)
; control group 2 (1 atopic eczema, 1 arduousness of study)
Participants Country: Finland
Setting: recruited via pamphlets at well-baby clinic
Number of participants: randomised 109; probiotic 55, control 54
Age: not reported, but participants were “1 month old infants”
Inclusion criteria: (1) the child was healthy, (2) the parents were willing to use the novel
slow-release pacifier, and (3) the child started receiving the tablet before the age of 2
months. In cases where the child did not start using the pacifier but the parents were
motivated to remain in the study, they were offered the possibility of delivering the
crushed tablet to the child using a spoon
Exclusion criteria: NR
Interventions Treatment group: the probiotic bacterium used was BB-12 (DSM 15 954; Chr. Hansen
A/S, Hoersholm, Denmark). 2 probiotic tablets per day via a novel slow-release pacifier
(pacifier contains a pouch in which the tablet is inserted); each tablet contained 5 billion
CFU of BB-12. Until 6 to 8 months of age, the children received the tablet via a small
pacifier, thereafter via a larger pacifier. The tablet in the small pacifier contained 100 mg
xylitol; the tablet in the larger pacifier contained 300 mg xylitol, both in addition to BB-
12. Duration: from age 1 to 2 months to 8 months
Comparator group: the control tablets contained xylitol alone. Duration: from age 1 to
2 months to 8 months
Outcomes Primary outcome(s): reported cumulative incidence of ARIs and doctor-diagnosedAOM
occurring before the age of 8 months
Secondary outcome(s): successful intestinal passage of BB-12 (Bifidobacterium animalis
subsp. lactis)
Notes Authors’ COIs: 1 author (TT) states “no conflict of interest”. 1 author (CL) lists an affili-
ation with Chr. Hansen (which donated the BB-12 probiotics) in the author affiliations,
but this is not noted in the COI. No information on COIs of the remaining authors
Funding: TT had no conflicts of interest. He was supported by personal grants from
the Emil Aaltonen and Sohlberg Foundations, Finnish Dental Society Apollonia, and
the Finnish Dental Association. The funding sources had no involvement in study de-
sign, interpretation of data, writing of the paper, or the decision to submit the paper
for publication. Chr. Hansen A/S (Hoersholm, Denmark) donated the BB-12 for the
probiotic tablets and helped in carrying out the faecal analysis of BB-12. The tablets were
manufactured by Oy Karl Fazer Ab (Vantaa, Finland). The pacifiers were manufactured
by Mekalasi Oy (Konnevesi, Finland). Neither Hansen, Fazer, or Mekalasi provided fi-
nancial support for this clinical study
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Taipale 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Study described as randomised; base-
line characteristics appear similar between
groups
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All of the study personnel and participants
were blinded to the treatment assignment
for the duration of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only 1 of the authors (ES) had the code,
but this author did not participate in pro-
ducing or analysing the data at any stage of
the trial and had no contact with the study
participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons provided.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias High risk TT had no conflicts of interest. He was
supported by personal grants from the
Emil Aaltonen and Sohlberg Foundations,
Finnish Dental Society Apollonia, and the
Finnish Dental Association. The funding
sources had no involvement in study de-
sign, interpretation of data, writing of the
paper, or the decision to submit the paper
for publication. Chr. Hansen A/S (Hoer-
sholm, Denmark) donated the BB-12 for
the probiotic tablets and helped in carrying
out the faecal analysis of BB-12. The tablets
were manufactured by Oy Karl Fazer Ab
(Vantaa, Finland). The pacifiers were man-
ufactured byMekalasi Oy (Konnevesi, Fin-
land). Neither Hansen, Fazer, or Mekalasi
provided financial support for this clinical
study. 1 author (TT) states “no conflict of
interest”. 1 author (CL) lists an affiliation
with Chr. Hansen (which donated the BB-
12 probiotics) in the author affiliations, but
this is not noted in the COI. No informa-
tion on COIs of the remaining authors
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Taipale 2016
Methods NB: this study reports the results of a 2-year follow-up of the participants in Taipale
2011 (see above)
Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: computer-generated randomisation list; blocks of 3 (see
Taipale 2011)
Blinding: double-blinded
Duration: 2-year follow-up of participants in Taipale 2011
Exclusions postrandomisation: none
Losses to follow-up: probiotic group: 17 did not receive tablet; control group: 17 did
not receive tablet
Non-adherence to protocol: probiotic group 6 (2GI complaints, 4 arduousness of study)
; control group 2 (1 atopic eczema, 1 arduousness of study)
Participants Country: Finland
Setting: originally recruited via pamphlets at well-baby clinics
Number of participants: randomised 109; probiotic 55, control 54 in original trial; this
study reports on those participants who completed the 2-year follow up: 32 probiotics,
35 control
Age: NR
Inclusion criteria: the inclusion criteria of the Taipale 2011 trial were that: (1) the child
was healthy, (2) the parents agreed to use the novel slow-release pacifier, and (3) the child
started to use the pacifier before the age of 2 months. In cases where the child did not
start using the pacifier but the parents were motivated to remain in the study, they were
offered the possibility of delivering the crushed tablet to the child using a spoon. Reasons
for not participating in the trial included moving out of the area, miscarriage, and lack
of interest in the trial
Exclusion criteria: NR
Interventions Treatment group: each probiotic tablet contained 5 billion CFU of Bifidobacterium
animalis subsp. lactis BB-12, in addition to bulking agent xylitol. The smaller tablet
contained 100 mg xylitol, whilst the larger tablet contained 300 mg xylitol. Test tablets
were administered from the age of 1 to 2 months with a novel slow-release pacifier which
contained a pouch in which the tablet was inserted. The children received the tablets
twice a day via a small pacifier (volume 120 µL) until 6 to 8 months of age, thereafter
via a larger pacifier (volume 250 µL) until the age of 2 years
Comparator group: the placebo tablet contained xylitol (the smaller tablet contained
100 mg xylitol, whilst the larger tablet contained 300 mg xylitol). The children received
the tablets twice a day via a small pacifier (volume 120 µL) until 6 to 8 months of age,
thereafter via a larger pacifier (volume 250 µL) until the age of 2 years
Outcomes Primary outcome(s): prevalence of overall acute infections occurring before the age of 2
years (ARTIs, AOM, GI, fever episodes)
Secondary outcome(s): successful intestinal passage of BB-12
Notes Authors’ COIs: TJT was supported by a personal grant from Finnish Dental Society
Apollonia. Disclosures: the authors declare that there are no conflicts of interest
Funding: Chr. Hansen A/S (Hoersholm, Denmark) donated the BB-12 and carried
out the faecal analyses of BB-12. Oy Karl Fazer Ab (Vantaa, Finland) manufactured
the tablets and Mekalasi Oy (Konnevesi, Finland) manufactured the pacifiers. Neither
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Taipale 2016 (Continued)
Hansen, Fazer, or Mekalasi provided financial support for this study. The role of the
funder (if any) in the conception, design, or conduct of the study or in the analysis or
interpretation of the data was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation list;
blocks of 3
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study personnel and participants were
blinded to treatment assignment for the du-
ration of the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data were analysed with SPSS by a blinded
statistician (KP).
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons provided.
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Unclear risk Authors’ COIs: TJT was supported by a
personal grant fromFinnish Dental Society
Apollonia. Disclosures: the authors declare
that there are no conflicts of interest
Funding: Chr. Hansen A/S (Hoersholm,
Denmark) donated the BB-12 and carried
out the faecal analyses of BB-12. Oy Karl
Fazer Ab (Vantaa, Finland) manufactured
the tablets and Mekalasi Oy (Konnevesi,
Finland) manufactured the pacifiers. Nei-
ther Hansen, Fazer, or Mekalasi provided
financial support for this study. The role of
the funder (if any) in the conception, de-
sign, or conduct of the study or in the anal-
ysis or interpretation of the data was not
reported
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Tano 2002
Methods Study design: 2-arm, placebo-controlled, randomised clinical study
Method of randomisation: randomisation performed by a technician with no access to
information about the included participants or the doctor involved; further details not
reported
Blinding: double-blinded
Duration: 4 months
Exclusions postrandomisation: none
Losses to follow-up: probiotic: 3 did not complete the scheduled 4-month treatment;
placebo: 1 did not complete the scheduled 4-month treatment
Non-adherence to protocol: probiotic: 2 excluded due to freezer with alpha-haemolytic
streptococci (AHS) suspension inadvertently being thawed; control: 1 excluded due to
freezer with AHS suspension inadvertently being thawed
Participants Country: Sweden
Setting: children referred to ENT department due to recurrent AOM
Number of participants: 43 “included” (not clear if this is the number randomised);
probiotic 21, placebo 22
Age (mean, range): probiotic: 21.5 months (range 9 to 42), placebo: 20.7 months (range
4 to 46)
Inclusion criteria: children referred to the ENT department in Boden and Umea because
of recurrent AOM; aged 3 years and younger, and with a history of at least 3 episodes of
AOM during the last 6 months or 6 episodes of AOM; aerated middle ears
Exclusion criteria: patients with secretory otitis media in 1 or both ears; severe underlying
diseases such as immunological deficiencies, valvular heart diseases, or wounds in the
nose or mouth
Interventions Treatment group: a suspension of 10% skim milk and 0.9% CFU/mL was used; strains
included: 2 strains of Streptococcus sanguis, 2 strains of S mitis, 1 strain of S oralis in equal
proportions. Spray once daily (1 puff 50 µL in each nostril) for 4 months
Comparator group: skim milk with 0.9% sodium chloride was used as a placebo control
and was kept frozen until thawed and used. Spray once daily (1 puff 50 µL in each
nostril) for 4 months
Outcomes Primary outcome(s): a reduction in AOM episodes (NB: this is not made explicit)
Secondary outcome(s): not clear. Other outcomes reported in the article: URI episodes,
AOM episodes, otalgia, serous otitis media (SOM), adverse events
Notes Authors’ COIs: NR
Funding: the present study was supported by the County Council of Norrbotten, the
Joint Committee North Medical Care Region (‘Visare Norr’), and the Swedish Medical
Research Council (No. K2001-73x-06578-19A). Essum AB prepared the bottles with
nasal spray. The role of the funder (if any) in the conception, design, or conduct of the
study or in the analysis or interpretation of the data was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Tano 2002 (Continued)
Random sequence generation (selection
bias)
Low risk Randomised by a technician with no access
to information about included participants
or doctor involved; baseline characteristics
appear similar for both groups
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both the investigator (KT) and the parents
were blinded to the drug
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk NR
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition reported for both arms, with rea-
sons provided.
Selective reporting (reporting bias) Unclear risk Outcomes not clearly identified.
Other bias High risk Authors’ COIs: NR
Funding: the present study was supported
by the County Council of Norrbotten, the
Joint Committee North Medical Care Re-
gion (‘Visare Norr’), and the SwedishMed-
ical Research Council (No. K2001-73x-
06578-19A). Essum AB prepared of the
bottles with nasal spray. The role of the fun-
der (if any) in the conception, design, or
conduct of the study or in the analysis or
interpretation of the data was not reported
AOM: acute otitis media
ARI: acute respiratory infection
CFU: colony-forming units
COI: conflict of interest
ENT: ear, nose, and throat
FEV1: forced expiratory volume in one second
GI: gastrointestinal
IL-8: interleukin-8
LRTI: lower respiratory tract infection
NR: not reported
SD: standard deviation
SOM: serous otitis media
TNF: tumour necrosis factor
URI: upper respiratory infection
URTI: upper respiratory tract infection
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agustina 2012 Wrong outcomes
Ahanchian 2016 Wrong outcomes
Arvola 1999 Wrong outcomes
Aryayev 2012 Wrong outcomes
Auinger 2013 Wrong population
Bellomo 1980 Wrong outcomes
Canani 2016 Wrong outcomes
Cazzola 2010 Wrong outcomes
Cobo 2006 Wrong outcomes
Collet 1993 Wrong intervention
Corsello 2016 Wrong outcomes
Coulthard 2004 Wrong study type
Crawford 2015 Wrong study type
Cáceres 2010 Wrong outcomes
Dekker 2017 Wrong outcomes
Di Pierro 2012 Wrong study type
Garaiova 2015 Wrong outcomes
Gerasimov 2012 Wrong outcomes
Gerasimov 2016 Wrong outcomes
Gonchar 2015 Wrong outcomes
Guillemard 2010 Wrong population
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Gutierrez-Castrellon 2014 Wrong outcomes
Hatakka 2001b Wrong study type
He 2005 Wrong outcomes
Hojsak 2009a Wrong outcomes
Hojsak 2009b Wrong outcomes
Hojsak 2010b Wrong outcomes
Hojsak 2015 Wrong outcomes
ISCTRN 2004 Clinical trial record only, picked up in literature searches; no publications resulting from this trial
Ito 2017 Wrong intervention
Jespersen 2015 Wrong population
Kaplan 1968 Wrong study type
Kloster 2008 Wrong outcomes
Kukkonen 2008 Wrong outcomes
Kumpu 2012 Wrong outcomes
Kumpu 2013 Wrong outcomes
Laursen 2017a Wrong outcomes
Lehtoranta 2012 Wrong outcomes
Li 2014 Wrong outcomes
Lin 2009 Wrong outcomes
Luoto 2014 Wrong outcomes
Maldonado 2010 Wrong outcomes
Maldonado 2011 Wrong outcomes
Marchisio 2010 Wrong intervention
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Marchisio 2016 Wrong study type
Marchisio 2017 Wrong study type
Marogna 2014 Wrong outcomes
Marseglia 2007 Wrong outcomes
Merenstein 2010 Wrong outcomes
Mizgier 2013 Wrong outcomes
Nocerino 2014 Wrong outcomes
Nocerino 2016 Wrong outcomes
Pitkaranta 2003 Conference abstract for a study that was included as a full article (Hatakka 2007a)
Prodeus 2016 Wrong outcomes
Puccio 2007 Wrong outcomes
Ringel-Kulka 2015 Wrong outcomes
Rivero 2004 Wrong outcomes
Río 2002 Wrong outcomes
Sazawal 2004 Wrong outcomes
Sazawal 2010 Wrong outcomes
Schrezenmeir 2004 Wrong outcomes
Skovbjerg 2009 Wrong outcomes
Smith 2016 Wrong outcomes
Stojkovic 2016 Wrong study type
Timby 2015 Wrong intervention
Vlieger 2009 Wrong outcomes
Weizman 2006 Wrong outcomes
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West 2008 Wrong outcomes
Wright 2009 Wrong population
Characteristics of ongoing studies [ordered by study ID]
ACTRN12618000130268
Trial name or title A randomised placebo controlled trial of the effect of BLIS probiotic, S. salivarius (K12) on otitis media (ear
infections) and upper respiratory tract infections amongst 6-24 month old children, as measured by medical
record events
Methods Quadruple-blind (participant, individuals administering treatment, outcome assessors, outcome analysts),
placebo-controlled, randomised clinical trial with 2 arms
Participants Infants 6 months old; both genders
Interventions Probiotic (Streptococcus salivarius K12), isomalt, maltodextrin, and natural flavour; placebo
Outcomes The primary outcome will be rate of doctor-recorded AOM in the 18 months the child takes part in the trial
Starting date Not yet started; recruitment anticipated to start February 2018, actual start date not listed
Contact information Prof Julian Crane, julian.crane@otago.ac.nz
Trial ID ACTRN12618000130268
Trial name or title BLIS-OM
Notes -
EUCTR2017-000820-83-FI
Trial name or title Otitis media and nasopharyngeal microbiome in children
Methods Open, randomised clinical trial with 2 arms
Participants Age 1 to 6 years, in day-care centre in the city of Oulu, Finland
Interventions Streptococcus salivarius K12 strain (oral powder in sachet); no treatment
Outcomes Primary endpoint is the positive S salivarius quantitative 16S RNA PCR result in time points 1 and 2 months,
e.g. after the 1 month use of the product and 1 month after that. Hence we are measuring the rate of S
salivarius colonisation, or the microbiological efficiency of the different products. Samples are to be taken
from controls as well since we do not know if the bacteria are able to transmit among children, and for how
long the desired result lasts
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EUCTR2017-000820-83-FI (Continued)
Starting date Unclear. Current status: ongoing
Contact information Oulu University Hospital, phone: +35883152011
Trial ID EUCTR2017-000820-83-FI
Trial name or title -
Notes -
ISRCTN53286030
Trial name or title A controlled trial of probiotics in the prevention of episodes of otitis media in general practice
Methods Blinding NR, randomised, placebo-controlled trial
Participants Children 6 to 11 months old, both genders
Interventions Probiotics (Lactobacillus and bifidobacteria); placebo
Outcomes Primary outcome: reported episodes of recurrent significant otalgia difference in proportions over 3 months
Starting date September 2003
Contact information Dr Ian Williamson, University of Southampton; igw@soton.ac.uk
Trial ID ISRCTN53286030
Trial name or title PIPO
Notes -
NCT01724203
Trial name or title Effect of 12-week probiotic supplementation on bacterial and viral infections in infants aged 6 to 12 months
Methods Double-blind (participant, investigator), placebo-controlled, randomised clinical trial with 3 arms
Participants Children aged 6 to 12 months, both genders
Interventions Arm 1: Lactobacillus rhamnosusHN001; arm 2: Bifidobacterium animalis subsp. lactis; arm 3: placebo
Outcomes Primary outcome: proportion of participants with 1 or more of confirmed bacterial or viral infections at any
time during the study
Starting date December 2012
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NCT01724203 (Continued)
Contact information Dr Xiaoyang Sheng, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (email/phone not
provided)
Trial ID NCT01724203
Trial name or title -
Notes -
NCT01909128
Trial name or title Fermented milk and fermented rice on the appearance of respiratory and gastrointestinal symptoms
Methods Quadruple-blind (participant, care provider, investigator, outcomes assessor), placebo-controlled, randomised
clinical trial with 3 arms
Participants Children aged 12 to 48 months, both genders
Interventions Arm 1: fermented milk with probiotic; arm 2: fermented rice with probiotic; arm 3: placebo
Outcomes Primary outcome: common respiratory and gastrointestinal infections
Starting date February 2013
Contact information Roberto Berni Canani, MD, PhD, Federico II University (email/phone not provided)
Trial ID NCT01909128
Trial name or title -
Notes Included as Nocerino 2017
NCT02221687
Trial name or title Evaluation of the efficacy and safety of an infant formula containing synbiotics and its effects on the incidence
of infectious diseases in the infant gut: a double-blind, randomised, controlled interventional study
Methods Triple-blind (participant, care provider, investigator), placebo-controlled, randomised clinical trial with 3
arms
Participants Children up to 5 weeks old, both genders
Interventions Synbiotic formula (standard formula enriched with prebiotic + probiotic); control formula (standard formula)
; no intervention (breast fed group)
Outcomes Primary outcome: cumulative number of infectious diarrhoea episodes per child during the first year of life
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NCT02221687 (Continued)
Starting date August 2014
Contact information Hugues Piloquet, Paediatrician (email/phone not provided)
Trial ID NCT02221687
Trial name or title GOLFIII
Notes -
NCT02802059
Trial name or title E. coli Nissle 1917 - suspension for infection prophylaxis
Methods Double-blind (participant, investigator), placebo-controlled, randomised clinical trial with 2 arms
Participants Age at inclusion: maximum 120 hours after birth, both genders
Interventions Escherichia coli strain Nissle 1917 (EcN-Suspension) probiotic bacteria; placebo
Outcomes Primary outcome: number of infections confirmed by a medical doctor
Starting date October 2015
Contact information Corinna Wolff, Dipl-Biophys; corinna.wolff@ardeypharm.de
Trial ID NCT02802059
Trial name or title RONi
Notes -
NCT03516409
Trial name or title Bio-Kult Infantis in AAD prevention in infants
Methods Open, placebo-controlled, randomised clinical trial with 2 arms
Participants Children 6 months to 35 months old, both genders
Interventions Bio-Kult Infantis (a multistrain probiotic formula); placebo (maltodextrin DE19)
Outcomes Primary outcome: incidence of antibiotic-associated diarrhoea
Starting date April 2018
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NCT03516409 (Continued)
Contact information Dr Salvatore Tripodi, UOC Paediatric Hospital “Sandro Pertini” (email/phone not provided)
Trial ID NCT03516409
Trial name or title -
Notes -
NCT03614117
Trial name or title Effect of a new probiotic strain on recurrent acute otitis media in children
Methods Quadruple-blind (participant, care provider, investigator, outcomes assessor), placebo-controlled, randomised
clinical trial with 3 arms
Participants Children 1 to 4 years old with recurrent AOM, and presence of AOM at the time of inclusion in the study
Interventions Arm 1: Lactobacillus salivarius PS7 for 6 months; arm 2: L salivarius PS 7 + placebo for 3 months each; arm
3: placebo supplement
Outcomes Primary outcome: number of AOM episodes
Starting date October 2018
Contact information Susana Manzano; susana.manzano@probisearch.com
Trial ID NCT03614117
Trial name or title PROMAR
Notes -
AAD: antibiotic-associated diarrhoea
AOM: acute otitis media
NR: not reported
PCR: polymerase chain reaction
RNA: ribonucleic acid
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D A T A A N D A N A L Y S E S
Comparison 1. Probiotics versus placebo or usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of children with
AOM (overall)
16 2961 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.63, 0.93]
2 Proportion of children with
AOM (by health status)
16 2961 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.63, 0.93]
2.1 Children prone to otitis
media
5 734 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.85, 1.11]
2.2 Children not prone to
otitis media
11 2227 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.49, 0.84]
3 Proportion of children with
AOM (by probiotic strain)
16 2961 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.63, 0.93]
3.1 Lactobacillus-containing 10 2055 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.54, 0.98]
3.2 Streptococcus-containing 6 906 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.60, 1.02]
4 Adverse events 4 395 Odds Ratio (M-H, Random, 95% CI) 1.54 [0.60, 3.94]
5 Difference in the use of
antibiotics
8 1768 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.51, 0.86]
5.1 Use of antibiotic for AOM 3 597 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.30, 1.32]
5.2 Use of antibiotic for other
infections
5 1171 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.45, 0.92]
6 Time off school for the child
(days)
5 1280 Mean Difference (IV, Random, 95% CI) -0.95 [-2.47, 0.57]
7 Difference in proportion of
children with other infections
11 3610 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.65, 0.87]
7.1 Acute respiratory
infections
10 2167 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.88]
7.2 Gastrointestinal infections 8 1443 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.57, 1.06]
8 Compliance with taking
probiotics
6 990 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.99, 1.05]
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Analysis 1.1. Comparison 1 Probiotics versus placebo or usual care, Outcome 1 Proportion of children with
AOM (overall).
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 1 Proportion of children with AOM (overall)
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 2013a 80/112 80/112 11.3 % 1.00 [ 0.85, 1.18 ]
Corsello 2017 8/66 13/60 3.8 % 0.56 [ 0.25, 1.26 ]
Di Nardo 2014 1/30 6/30 0.8 % 0.17 [ 0.02, 1.30 ]
Di Pierro 2016 49/111 89/111 10.5 % 0.55 [ 0.44, 0.69 ]
Hatakka 2001a 79/252 101/261 10.3 % 0.81 [ 0.64, 1.03 ]
Hatakka 2007a 97/135 87/134 11.3 % 1.11 [ 0.94, 1.30 ]
Hojsak 2010a 8/139 13/142 3.5 % 0.63 [ 0.27, 1.47 ]
Hojsak 2016 15/104 18/106 5.2 % 0.85 [ 0.45, 1.59 ]
Karpova 2015 2/113 5/106 1.2 % 0.38 [ 0.07, 1.89 ]
Marchisio 2015 35/50 40/47 10.6 % 0.82 [ 0.66, 1.02 ]
Nocerino 2017 8/264 18/127 3.8 % 0.21 [ 0.10, 0.48 ]
Rautava 2009 7/32 20/40 4.4 % 0.44 [ 0.21, 0.90 ]
Roos 2001a 21/53 28/55 7.7 % 0.78 [ 0.51, 1.19 ]
Taipale 2011 9/34 6/35 3.2 % 1.54 [ 0.62, 3.87 ]
Taipale 2016 19/31 21/33 8.2 % 0.96 [ 0.66, 1.41 ]
Tano 2002 7/16 8/20 4.0 % 1.09 [ 0.51, 2.37 ]
Total (95% CI) 1542 1419 100.0 % 0.77 [ 0.63, 0.93 ]
Total events: 445 (Probiotic), 553 (Comparator)
Heterogeneity: Tau2 = 0.08; Chi2 = 53.07, df = 15 (P<0.00001); I2 =72%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours probiotic Favours comparator
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Analysis 1.2. Comparison 1 Probiotics versus placebo or usual care, Outcome 2 Proportion of children with
AOM (by health status).
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 2 Proportion of children with AOM (by health status)
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Children prone to otitis media
Cohen 2013a 80/112 80/112 11.3 % 1.00 [ 0.85, 1.18 ]
Hatakka 2007a 97/135 87/134 11.3 % 1.11 [ 0.94, 1.30 ]
Marchisio 2015 35/50 40/47 10.6 % 0.82 [ 0.66, 1.02 ]
Roos 2001a 21/53 28/55 7.7 % 0.78 [ 0.51, 1.19 ]
Tano 2002 7/16 8/20 4.0 % 1.09 [ 0.51, 2.37 ]
Subtotal (95% CI) 366 368 45.0 % 0.97 [ 0.85, 1.11 ]
Total events: 240 (Probiotic), 243 (Comparator)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.90, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Children not prone to otitis media
Corsello 2017 8/66 13/60 3.8 % 0.56 [ 0.25, 1.26 ]
Di Nardo 2014 1/30 6/30 0.8 % 0.17 [ 0.02, 1.30 ]
Di Pierro 2016 49/111 89/111 10.5 % 0.55 [ 0.44, 0.69 ]
Hatakka 2001a 79/252 101/261 10.3 % 0.81 [ 0.64, 1.03 ]
Hojsak 2010a 8/139 13/142 3.5 % 0.63 [ 0.27, 1.47 ]
Hojsak 2016 15/104 18/106 5.2 % 0.85 [ 0.45, 1.59 ]
Karpova 2015 2/113 5/106 1.2 % 0.38 [ 0.07, 1.89 ]
Nocerino 2017 8/264 18/127 3.8 % 0.21 [ 0.10, 0.48 ]
Rautava 2009 7/32 20/40 4.4 % 0.44 [ 0.21, 0.90 ]
Taipale 2011 9/34 6/35 3.2 % 1.54 [ 0.62, 3.87 ]
Taipale 2016 19/31 21/33 8.2 % 0.96 [ 0.66, 1.41 ]
Subtotal (95% CI) 1176 1051 55.0 % 0.64 [ 0.49, 0.84 ]
Total events: 205 (Probiotic), 310 (Comparator)
Heterogeneity: Tau2 = 0.09; Chi2 = 24.12, df = 10 (P = 0.01); I2 =59%
Test for overall effect: Z = 3.26 (P = 0.0011)
Total (95% CI) 1542 1419 100.0 % 0.77 [ 0.63, 0.93 ]
0.05 0.2 1 5 20
Favours probiotic Favours comparator
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(. . . Continued)
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 445 (Probiotic), 553 (Comparator)
Heterogeneity: Tau2 = 0.08; Chi2 = 53.07, df = 15 (P<0.00001); I2 =72%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Chi2 = 7.36, df = 1 (P = 0.01), I2 =86%
0.05 0.2 1 5 20
Favours probiotic Favours comparator
Analysis 1.3. Comparison 1 Probiotics versus placebo or usual care, Outcome 3 Proportion of children with
AOM (by probiotic strain).
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 3 Proportion of children with AOM (by probiotic strain)
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Lactobacillus-containing
Corsello 2017 8/66 13/60 3.8 % 0.56 [ 0.25, 1.26 ]
Di Nardo 2014 1/30 6/30 0.8 % 0.17 [ 0.02, 1.30 ]
Hatakka 2001a 79/252 101/261 10.3 % 0.81 [ 0.64, 1.03 ]
Hatakka 2007a 97/135 87/134 11.3 % 1.11 [ 0.94, 1.30 ]
Hojsak 2010a 8/139 13/142 3.5 % 0.63 [ 0.27, 1.47 ]
Hojsak 2016 15/104 18/106 5.2 % 0.85 [ 0.45, 1.59 ]
Nocerino 2017 8/264 18/127 3.8 % 0.21 [ 0.10, 0.48 ]
Rautava 2009 7/32 20/40 4.4 % 0.44 [ 0.21, 0.90 ]
Taipale 2011 9/34 6/35 3.2 % 1.54 [ 0.62, 3.87 ]
Taipale 2016 19/31 21/33 8.2 % 0.96 [ 0.66, 1.41 ]
Subtotal (95% CI) 1087 968 54.7 % 0.72 [ 0.54, 0.98 ]
0.1 0.2 0.5 1 2 5 10
Favours probiotic Favours comparator
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(. . . Continued)
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 251 (Probiotic), 303 (Comparator)
Heterogeneity: Tau2 = 0.13; Chi2 = 32.55, df = 9 (P = 0.00016); I2 =72%
Test for overall effect: Z = 2.10 (P = 0.036)
2 Streptococcus-containing
Cohen 2013a 80/112 80/112 11.3 % 1.00 [ 0.85, 1.18 ]
Di Pierro 2016 49/111 89/111 10.5 % 0.55 [ 0.44, 0.69 ]
Karpova 2015 2/113 5/106 1.2 % 0.38 [ 0.07, 1.89 ]
Marchisio 2015 35/50 40/47 10.6 % 0.82 [ 0.66, 1.02 ]
Roos 2001a 21/53 28/55 7.7 % 0.78 [ 0.51, 1.19 ]
Tano 2002 7/16 8/20 4.0 % 1.09 [ 0.51, 2.37 ]
Subtotal (95% CI) 455 451 45.3 % 0.78 [ 0.60, 1.02 ]
Total events: 194 (Probiotic), 250 (Comparator)
Heterogeneity: Tau2 = 0.06; Chi2 = 19.45, df = 5 (P = 0.002); I2 =74%
Test for overall effect: Z = 1.81 (P = 0.071)
Total (95% CI) 1542 1419 100.0 % 0.77 [ 0.63, 0.93 ]
Total events: 445 (Probiotic), 553 (Comparator)
Heterogeneity: Tau2 = 0.08; Chi2 = 53.07, df = 15 (P<0.00001); I2 =72%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours probiotic Favours comparator
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Analysis 1.4. Comparison 1 Probiotics versus placebo or usual care, Outcome 4 Adverse events.
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 4 Adverse events
Study or subgroup Probiotic Comparator Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Marchisio 2015 21/50 7/47 31.5 % 4.14 [ 1.55, 11.02 ]
Rautava 2009 3/38 4/43 20.6 % 0.84 [ 0.17, 4.00 ]
Roos 2001a 22/53 25/55 36.5 % 0.85 [ 0.40, 1.82 ]
Taipale 2011 2/55 1/54 11.4 % 2.00 [ 0.18, 22.73 ]
Total (95% CI) 196 199 100.0 % 1.54 [ 0.60, 3.94 ]
Total events: 48 (Probiotic), 37 (Comparator)
Heterogeneity: Tau2 = 0.48; Chi2 = 6.83, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
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Analysis 1.5. Comparison 1 Probiotics versus placebo or usual care, Outcome 5 Difference in the use of
antibiotics.
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 5 Difference in the use of antibiotics
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Use of antibiotic for AOM
Hojsak 2016 8/139 13/142 6.8 % 0.63 [ 0.27, 1.47 ]
Karpova 2015 1/113 7/106 1.5 % 0.13 [ 0.02, 1.07 ]
Marchisio 2015 35/50 39/47 19.9 % 0.84 [ 0.68, 1.05 ]
Subtotal (95% CI) 302 295 28.3 % 0.63 [ 0.30, 1.32 ]
Total events: 44 (Probiotic), 59 (Comparator)
Heterogeneity: Tau2 = 0.24; Chi2 = 4.76, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Use of antibiotic for other infections
Corsello 2017 20/66 30/60 14.0 % 0.61 [ 0.39, 0.95 ]
Hatakka 2001a 111/252 140/261 21.0 % 0.82 [ 0.69, 0.98 ]
Nocerino 2017 58/264 64/127 18.3 % 0.44 [ 0.33, 0.58 ]
Rautava 2009 10/32 24/40 11.1 % 0.52 [ 0.29, 0.92 ]
Taipale 2011 10/34 8/35 7.4 % 1.29 [ 0.58, 2.87 ]
Subtotal (95% CI) 648 523 71.7 % 0.65 [ 0.45, 0.92 ]
Total events: 209 (Probiotic), 266 (Comparator)
Heterogeneity: Tau2 = 0.11; Chi2 = 17.15, df = 4 (P = 0.002); I2 =77%
Test for overall effect: Z = 2.43 (P = 0.015)
Total (95% CI) 950 818 100.0 % 0.66 [ 0.51, 0.86 ]
Total events: 253 (Probiotic), 325 (Comparator)
Heterogeneity: Tau2 = 0.08; Chi2 = 23.16, df = 7 (P = 0.002); I2 =70%
Test for overall effect: Z = 3.06 (P = 0.0022)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 1.6. Comparison 1 Probiotics versus placebo or usual care, Outcome 6 Time off school for the
child (days).
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 6 Time off school for the child (days)
Study or subgroup Probiotic Comparator
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Corsello 2017 66 2 (4.14) 60 8 (15.8) 10.6 % -6.00 [ -10.12, -1.88 ]
Hatakka 2001a 252 4.9 (4.45) 261 5.8 (4.53) 43.3 % -0.90 [ -1.68, -0.12 ]
Hojsak 2010a 139 3.1 (63.2) 106 5.1 (70) 0.8 % -2.00 [ -18.97, 14.97 ]
Hojsak 2016 104 4.45 (4) 106 4.17 (6) 34.9 % 0.28 [ -1.10, 1.66 ]
Stecksen-Blicks 2009 110 13.4 (12) 76 13.4 (15.8) 10.3 % 0.0 [ -4.20, 4.20 ]
Total (95% CI) 671 609 100.0 % -0.95 [ -2.47, 0.57 ]
Heterogeneity: Tau2 = 1.23; Chi2 = 8.67, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Probiotics versus placebo or usual care, Outcome 7 Difference in proportion of
children with other infections.
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 7 Difference in proportion of children with other infections
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acute respiratory infections
Corsello 2017 22/66 24/60 5.2 % 0.83 [ 0.53, 1.32 ]
Di Pierro 2016 18/111 54/111 5.2 % 0.33 [ 0.21, 0.53 ]
Hatakka 2001a 18/252 22/261 3.8 % 0.85 [ 0.47, 1.54 ]
Hojsak 2010a 54/139 87/142 8.4 % 0.63 [ 0.50, 0.81 ]
Hojsak 2016 44/104 43/106 7.1 % 1.04 [ 0.76, 1.44 ]
Karpova 2015 4/113 14/106 1.5 % 0.27 [ 0.09, 0.79 ]
Nocerino 2017 145/264 89/127 9.8 % 0.78 [ 0.67, 0.92 ]
Rautava 2009 22/32 31/40 7.7 % 0.89 [ 0.67, 1.18 ]
Taipale 2011 22/34 33/35 8.1 % 0.69 [ 0.53, 0.89 ]
Taipale 2016 27/31 33/33 10.0 % 0.87 [ 0.75, 1.01 ]
Subtotal (95% CI) 1146 1021 66.8 % 0.74 [ 0.62, 0.88 ]
Total events: 376 (Probiotic), 430 (Comparator)
Heterogeneity: Tau2 = 0.05; Chi2 = 30.30, df = 9 (P = 0.00039); I2 =70%
Test for overall effect: Z = 3.48 (P = 0.00049)
2 Gastrointestinal infections
Cohen 2013a 52/112 46/112 7.5 % 1.13 [ 0.84, 1.52 ]
Corsello 2017 12/66 24/66 3.8 % 0.50 [ 0.27, 0.91 ]
Hojsak 2010a 16/139 26/142 4.0 % 0.63 [ 0.35, 1.12 ]
Hojsak 2016 14/104 11/106 2.8 % 1.30 [ 0.62, 2.72 ]
Nocerino 2017 41/264 38/127 6.2 % 0.52 [ 0.35, 0.76 ]
Rautava 2009 1/32 6/40 0.5 % 0.21 [ 0.03, 1.64 ]
Taipale 2011 9/34 7/35 2.2 % 1.32 [ 0.56, 3.15 ]
Taipale 2016 18/31 23/33 6.3 % 0.83 [ 0.57, 1.21 ]
Subtotal (95% CI) 782 661 33.2 % 0.78 [ 0.57, 1.06 ]
Total events: 163 (Probiotic), 181 (Comparator)
Heterogeneity: Tau2 = 0.10; Chi2 = 17.78, df = 7 (P = 0.01); I2 =61%
0.2 0.5 1 2 5
Favours probiotic Favours comparator
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(. . . Continued)
Study or subgroup Probiotic Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 1928 1682 100.0 % 0.75 [ 0.65, 0.87 ]
Total events: 539 (Probiotic), 611 (Comparator)
Heterogeneity: Tau2 = 0.05; Chi2 = 47.20, df = 17 (P = 0.00011); I2 =64%
Test for overall effect: Z = 3.89 (P = 0.000099)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.2 0.5 1 2 5
Favours probiotic Favours comparator
Analysis 1.8. Comparison 1 Probiotics versus placebo or usual care, Outcome 8 Compliance with taking
probiotics.
Review: Probiotics for preventing acute otitis media in children
Comparison: 1 Probiotics versus placebo or usual care
Outcome: 8 Compliance with taking probiotics
Study or subgroup Probiotics Comparator Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cohen 2013a 104/112 103/112 19.0 % 1.01 [ 0.94, 1.09 ]
Hatakka 2007a 51/53 53/55 19.5 % 1.00 [ 0.93, 1.08 ]
Hojsak 2010a 127/139 127/142 18.4 % 1.02 [ 0.95, 1.10 ]
Hojsak 2016 99/104 99/106 24.2 % 1.02 [ 0.95, 1.09 ]
Marchisio 2015 50/50 47/50 17.0 % 1.06 [ 0.98, 1.15 ]
Taipale 2016 26/32 28/35 1.9 % 1.02 [ 0.80, 1.28 ]
Total (95% CI) 490 500 100.0 % 1.02 [ 0.99, 1.05 ]
Total events: 457 (Probiotics), 457 (Comparator)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.44, df = 5 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours probiotic Favours comparator
82Probiotics for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Bibliographic database search strategies
PubMed (National Library of Medicine)
(Probiotics[Mesh]OR “Synbiotics”[Mesh]ORLactobacillus[Mesh]ORBifidobacterium[Mesh]ORSaccharomyces[Mesh]OR “Strep-
tococcus thermophilus”[Mesh] OR “Cultured Milk Products”[Mesh] OR Antibiosis[Mesh] OR “Lactococcus”[Mesh] OR Probi-
otics[tiab] OR Probiotic[tiab] OR Synbiotics[tiab] OR Synbiotic[tiab] OR Lactobacillus[tiab] OR Lactobacilli[tiab] OR Bifidobacte-
ria[tiab] OR Bifidobacterium[tiab] OR Saccharomyces[tiab] OR Saccharomyce[tiab] OR “Microbial dietary supplements”[tiab] OR
Yoghurt[tiab] OR “Fermented milk”[tiab] OR “Cultured Milk”[tiab] OR “Fermented Dairy”[tiab] OR Acidophilus[tiab] OR An-
tibiosis[tiab] OR “Microbial Antagonism”[tiab] OR “Microbial Antagonisms”[tiab] OR “Bacterial Interferences”[tiab] OR “Bacterial
Interference”[tiab] OR “Streptococcus thermophilus”[tiab] OR “Bacillus laterosporus”[tiab] OR “Pediococcus acidilactici”[tiab] OR
Lactococcus[tiab] OR Lactis[tiab])
AND
(“Respiratory Tract Infections”[Mesh] OR “Respiratory tract infection”[tiab] OR “Respiratory tract infections”[tiab] OR “Respiratory
infection”[tiab] OR “Respiratory infections”[tiab] OR urti[tiab] OR uri[tiab] OR ari[tiab] OR “Otitis Media”[Mesh] OR “Otitis
Media”[tiab] OR “Glue ear”[tiab] OR AOM[tiab] OROME[tiab] OR (“Middle Ear”[tiab] AND (Infection[tiab] OR Infections[tiab]
OR Inflammation[tiab] OR Inflammations[tiab])))
AND
((Randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR randomised[tiab] OR placebo[tiab] OR
“drug therapy”[sh] OR randomly[tiab] OR trial[tiab] OR groups[tiab])
NOT
(Animals[Mesh] not (Animals[Mesh] and Humans[Mesh])))
CENTRAL (Cochrane Central Register of Controlled Trials)
([mh Probiotics] OR [mh Synbiotics] OR [mh Lactobacillus] OR [mhBifidobacterium] OR [mh Saccharomyces] OR [mh “Streptococ-
cus thermophilus”] OR [mh “Cultured Milk Products”] OR [mh Antibiosis] OR [mh Lactococcus] OR Probiotics:ti,ab OR Probiotic:
ti,abOR Synbiotics:ti,ab OR Synbiotic:ti,ab ORLactobacillus:ti,ab OR Lactobacilli:ti,ab ORBifidobacteria:ti,ab ORBifidobacterium:
ti,ab OR Saccharomyces:ti,ab OR Saccharomyce:ti,ab OR “Microbial dietary supplements”:ti,ab OR Yoghurt:ti,ab OR “Fermented
milk”:ti,ab OR “Cultured Milk”:ti,ab OR “Fermented Dairy”:ti,ab OR Acidophilus:ti,ab OR Antibiosis:ti,ab OR “Microbial Antago-
nism”:ti,ab OR “Microbial Antagonisms”:ti,ab OR “Bacterial Interferences”:ti,ab OR “Bacterial Interference”:ti,ab OR “Streptococcus
thermophilus”:ti,ab OR “Bacillus laterosporus”:ti,ab OR “Pediococcus acidilactici”:ti,ab OR Lactococcus:ti,ab OR Lactis:ti,ab)
AND
([mh “Respiratory Tract Infections”] OR “Respiratory tract infection”:ti,ab OR “Respiratory tract infections”:ti,ab OR “Respiratory
infection”:ti,ab OR “Respiratory infections”:ti,ab OR urti:ti,ab OR uri:ti,ab OR ari:ti,ab OR [mh “Otitis Media”] OR “Otitis Media”:
ti,ab OR “Glue ear”:ti,ab OR AOM:ti,ab OR OME:ti,ab OR (“Middle Ear”:ti,ab AND (Infection:ti,ab OR Infections:ti,ab OR
Inflammation:ti,ab OR Inflammations:ti,ab)))
Embase (via Elsevier)
(’probiotic agent’/exp OR ’synbiotic agent’/exp OR ’Lactobacillus’/exp OR ’Bifidobacterium’/exp OR ’Saccharomyces’/exp OR ’Strep-
tococcus thermophilus’/exp OR ’fermented milk product’/exp OR ’Antibiosis’/exp OR ’Lactococcus’/exp OR Probiotics:ti,ab OR
Probiotic:ti,ab OR Synbiotics:ti,ab OR Synbiotic:ti,ab OR Lactobacillus:ti,ab OR Lactobacilli:ti,ab OR Bifidobacteria:ti,ab OR Bifi-
dobacterium:ti,ab OR Saccharomyces:ti,ab OR Saccharomyce:ti,ab OR “Microbial dietary supplements”:ti,ab OR Yoghurt:ti,ab OR
“Fermented milk”:ti,ab OR “Cultured Milk”:ti,ab OR “Fermented Dairy”:ti,ab OR Acidophilus:ti,ab OR Antibiosis:ti,ab OR “Mi-
crobial Antagonism”:ti,ab OR “Microbial Antagonisms”:ti,ab OR “Bacterial Interferences”:ti,ab OR “Bacterial Interference”:ti,ab OR
“Streptococcus thermophilus”:ti,ab OR “Bacillus laterosporus”:ti,ab OR “Pediococcus acidilactici”:ti,ab OR Lactococcus:ti,ab OR Lac-
tis:ti,ab)
AND
(’respiratory tract infection’/exp OR “Respiratory tract infection”:ti,ab OR “Respiratory tract infections”:ti,ab OR “Respiratory infec-
tion”:ti,ab OR “Respiratory infections”:ti,ab ORurti:ti,abOR uri:ti,ab OR ari:ti,ab OR ’OtitisMedia’/expOR “Otitis Media”:ti,ab OR
“Glue ear”:ti,ab OR AOM:ti,ab OR OME:ti,ab OR (“Middle Ear”:ti,ab AND (Infection:ti,ab OR Infections:ti,ab OR Inflammation:
ti,ab OR Inflammations:ti,ab)))
AND
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(random* OR factorial OR crossover OR placebo OR blind OR blinded OR assign OR assigned OR allocate OR allocated OR
’crossover procedure’/expOR ’double-blind procedure’/expOR ’randomized controlled trial’/expOR ’single-blind procedure’/expNOT
(’animal’/exp NOT (’animal’/exp AND ’human’/exp)))
AND
[embase]/lim
CINAHL
((MH “Probiotics+”) OR (MH “Lactobacillus+”) OR (MH “Bifidobacterium+”) OR (MH “Saccharomyces+”) OR (MH “Strepto-
coccus+”) OR (MH “Cultured Milk Products+”) OR (MH “Antibiosis+”) OR TI Probiotics OR AB Probiotics OR TI Probiotic OR
AB Probiotic OR TI Synbiotics OR AB Synbiotics OR TI Synbiotic OR AB Synbiotic OR TI Lactobacillus OR AB Lactobacillus
OR TI Lactobacilli OR AB Lactobacilli OR TI Bifidobacteria OR AB Bifidobacteria OR TI Bifidobacterium OR AB Bifidobacterium
OR TI Saccharomyces OR AB Saccharomyces OR TI Saccharomyce OR AB Saccharomyce OR TI “Microbial dietary supplements”
OR AB “Microbial dietary supplements” OR TI Yoghurt OR AB Yoghurt OR TI “Fermented milk” OR AB “Fermented milk” OR
TI “Cultured Milk” OR AB “Cultured Milk” OR TI “Fermented Dairy” OR AB “Fermented Dairy” OR TI Acidophilus OR AB
Acidophilus OR TI Antibiosis OR AB Antibiosis OR TI “Microbial Antagonism” OR AB “Microbial Antagonism” OR TI “Microbial
Antagonisms” OR AB “Microbial Antagonisms” OR TI “Bacterial Interferences” OR AB “Bacterial Interferences” OR TI “Bacterial
Interference” OR AB “Bacterial Interference” OR TI “Streptococcus thermophilus” OR AB “Streptococcus thermophilus” OR TI
“Bacillus laterosporus” OR AB “Bacillus laterosporus” OR TI “Pediococcus acidilactici” OR AB “Pediococcus acidilactici” OR TI
Lactococcus OR AB Lactococcus OR TI Lactis OR AB Lactis)
AND
((MH “Respiratory Tract Infections+”) OR TI “Respiratory tract infection” OR AB “Respiratory tract infection” OR TI “Respiratory
tract infections”ORAB“Respiratory tract infections”ORTI “Respiratory infection”ORAB“Respiratory infection”ORTI “Respiratory
infections” OR AB “Respiratory infections” OR TI urti OR AB urti OR TI uri OR AB uri OR TI ari OR AB ari OR (MH “Otitis
Media+”) OR TI “Otitis Media” OR AB “Otitis Media” OR TI “Glue ear” OR AB “Glue ear” OR TI AOM OR AB AOM OR TI
OME OR AB OME OR (TI “Middle Ear” OR AB “Middle Ear” AND (TI Infection OR AB Infection OR TI Infections OR AB
Infections OR TI Inflammation OR AB Inflammation OR TI Inflammations OR AB Inflammations)))
AND
((MH “Clinical Trials+”) OR (MH “Quantitative Studies”) ORTI placebo*ORABplacebo*OR (MH “Placebos”) OR (MH “Random
Assignment”) OR TI random* OR AB random* OR TI ((singl* or doubl* or tripl* or trebl*) W1 (blind* or mask*)) OR AB ((singl*
or doubl* or tripl* or trebl*) W1 (blind* or mask*)) OR TI clinic* trial* OR AB clinic* trial* OR PT clinical trial)
Web of Science
(Probiotics OR Synbiotics ORLactobacillus ORBifidobacterium ORSaccharomyces OR “Streptococcus thermophilus” OR “Cultured
Milk Products” OR Antibiosis OR Lactococcus OR Probiotics OR Probiotic OR Synbiotics OR Synbiotic OR Lactobacillus OR
Lactobacilli OR Bifidobacteria OR Bifidobacterium OR Saccharomyces OR Saccharomyce OR “Microbial dietary supplements”
OR Yoghurt OR “Fermented milk” OR “Cultured Milk” OR “Fermented Dairy” OR Acidophilus OR Antibiosis OR “Microbial
Antagonism”OR“Microbial Antagonisms”OR “Bacterial Interferences”OR “Bacterial Interference”OR “Streptococcus thermophilus”
OR “Bacillus laterosporus” OR “Pediococcus acidilactici” OR Lactococcus OR Lactis)
AND
(“Respiratory Tract Infections” OR “Respiratory tract infection” OR “Respiratory tract infections” OR “Respiratory infection” OR
“Respiratory infections” OR urti OR uri OR ari OR “Otitis Media” OR “Otitis Media” OR “Glue ear” OR AOM OR OME OR
(“Middle Ear” AND (Infection OR Infections OR Inflammation OR Inflammations)))
AND
(TS=(random* or placebo* or allocat* or crossover* or “cross over” or ((singl* or doubl*) NEAR/1 blind*)) OR TI=(trial))
LILACS
(Probiotics OR Synbiotics ORLactobacillus ORBifidobacterium ORSaccharomyces OR “Streptococcus thermophilus” OR “Cultured
Milk Products” OR Antibiosis OR Lactococcus OR Probiotics OR Probiotic OR Synbiotics OR Synbiotic OR Lactobacillus OR
Lactobacilli OR Bifidobacteria OR Bifidobacterium OR Saccharomyces OR Saccharomyce OR “Microbial dietary supplements”
OR Yoghurt OR “Fermented milk” OR “Cultured Milk” OR “Fermented Dairy” OR Acidophilus OR Antibiosis OR “Microbial
Antagonism”OR“Microbial Antagonisms”OR “Bacterial Interferences”OR “Bacterial Interference”OR “Streptococcus thermophilus”
OR “Bacillus laterosporus” OR “Pediococcus acidilactici” OR Lactococcus OR Lactis)
AND
(“Respiratory Tract Infections” OR “Respiratory tract infection” OR “Respiratory tract infections” OR “Respiratory infection” OR
“Respiratory infections” OR urti OR uri OR ari OR “Otitis Media” OR “Otitis Media” OR “Glue ear” OR AOM OR OME OR
(“Middle Ear” AND (Infection OR Infections OR Inflammation OR Inflammations)))
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AND
(random* or placebo* or allocat* or crossover* or “cross over” or blind* OR trial)
Appendix 2. Trial registry search strategies
ClinicalTrials.gov
(Probiotics OR Probiotic OR Synbiotics OR Synbiotic OR Lactobacillus OR Lactobacilli OR milk OR Acidophilus OR Yoghurt)
AND (“Otitis Media” OR “Glue ear” OR AOMOR OME OR “Middle Ear Infection”)
WHO ICTRP
Probiotics AND “Otitis Media” OR Probiotic AND “Otitis Media” OR Synbiotics AND “Otitis Media” OR Synbiotic AND “Otitis
Media” OR Lactobacillus AND “Otitis Media” OR Lactobacilli AND “Otitis Media” OR milk AND “Otitis Media” OR Acidophilus
AND “Otitis Media” OR Yoghurt AND “Otitis Media”
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Develop the search strategy: JC
Run the search strategy: JC
Obtain copies of trials: JC
Select which trials to include: AMS, JC, FI, BJ
Extract data from trials: AMS, FI, BJ
Enter data into Review Manager 5: AMS
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S O U R C E S O F S U P P O R T
Internal sources
• There are no internal sources of support to report, Other.
External sources
• There are no external sources of support to report, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Differences from the protocol:
1. Study population: the protocol stated that the population of interest is children (aged ≤ 18 years) diagnosed with acute otitis
media (AOM) by a clinician. Because this review looks at the role of probiotics in preventing AOM, we broadened the population to
include any children (aged ≤ 18 years), still including children diagnosed with AOM.
2. Electronic searches: the protocol stated that we would contact trial investigators for unpublished data. The status of trials
categorised as ’ongoing studies’ is as follows: not yet started or ongoing (five trials); contact information not available (two trials);
already published (publication included in the present review) (one trial); awaiting response from investigators (one trial)
(ISRCTN53286030).
3. Electronic searches: our protocol specified that we would use the ’similar articles’ feature in PubMed and shared citation matcher
in Web of Science. However, as forward and backward citation searches did not yield any additional included trials, we did not expect
to find any additional included trials this way.
4. Subgroup analysis: we planned to carry out the following subgroup analyses: (1) child’s age (≤ two years old), (2) type of
probiotic, (3) children with severe AOM, (4) trials that included a co-intervention. (1) The first subgroup analysis was planned
because the initial Population Intervention Comparison Outcome (PICO) stated that included trials will have as their population
children diagnosed with AOM, and there is no consensus on the benefit of antibiotics in AOM in children younger than two years
old and guidelines recommend selective use of antibiotics for AOM in children older than two years old (Rovers 2006). As the
population was amended to include all children, this subgroup analysis was omitted. (2) We did conduct an analysis by probiotic type
(see Analysis 1.3). (3) We did not conduct a subgroup analysis by severity of AOM, as this outcome was reported by only one
included trial. (4) We did not conduct a subgroup analysis by co-intervention because in only one trial all children (both groups)
received a co-intervention (Roos 2001a).
5. Sensitivity analysis: we planned to carry out a sensitivity analysis on including versus excluding trials with two or more domains
rated as at high risk of bias, however this was not performed as only one included study rated two domains as at high risk of bias.
6. Primary outcome was specified as ’incidence of AOM’ in the protocol. This was reported as ’proportion of children with AOM’
in the review due to variation in the time points at which studies reported the outcome.
7. Secondary outcome was specified as ’difference between probiotic and non-probiotic groups in use of antibiotics to treat AOM
(e.g. dose, duration)’ in the protocol. This was reported as ’difference in the use of antibiotics’ in the review to more accurately refect
the evidence available for meta-analyses.
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8. ’Summary of findings’ table: the protocol stated that we would create a ’Summary of findings’ table using the following
outcomes: incidence of AOM, severity of AOM, adverse events, median duration of AOM episodes, difference between groups in
antibiotic use, time off school (child), time off work (parent or carer). Due to a paucity of data and change in how the primary
outcome was reported (proportion of children with AOM), we instead reported the following outcomes: proportion of children with
AOM, proportion of children with AOM among children not prone to AOM, proportion of children with AOM among children
prone to AOM, severity of AOM, adverse events, time off school for child, difference in antibiotic use, difference in proportion of
children with other infections.
9. Three subgroup analyses were not prespecified but were conducted because there were sufficient data available for pooling:
difference in the use of antibiotics (subgroups: for AOM, for other infections); difference in other infections (subgroups: reduction in
acute respiratory infections, reduction in gastrointestinal infections); and proportion of children with AOM (children prone to AOM,
children not prone to AOM).
10. Authorship: one of the protocol authors (Elaine Beller) was not involved in the systematic review itself and is thus not listed as
an author here.
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